drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB01357 | DB06372 | 890 | 259 | [
"DDInter1160",
"DDInter1594"
] | Mestranol | Rilonacept | The 3-methyl ether of ethinyl estradiol. It must be demethylated to be biologically active. It is used as the estrogen component of many combination ORAL contraceptives. | Rilonacept is a dimeric fusion protein consisting of portions of IL-1R and the IL-1R accessory protein linked to the Fc portion of immunoglobulin G1. Rilonacept functions as an interleukin 1 inhibitor and is used in the treatment of CAPS, also known as cryopyrin-associated periodic syndromes, including familial cold au... | Moderate | 1 | [
[
[
890,
24,
259
]
],
[
[
890,
1,
1336
],
[
1336,
24,
259
]
],
[
[
890,
63,
1573
],
[
1573,
24,
259
]
],
[
[
890,
25,
350
],
[
350,
... | [
[
[
"Mestranol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilonacept"
]
],
[
[
"Mestranol",
"{u} (Compound) resembles {v} (Compound)",
"Etonogestrel"
],
[
"Etonogestrel",
"{u} may cause a moder... | Mestranol (Compound) resembles Etonogestrel (Compound) and Etonogestrel may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept
Mestranol may cause a moderate interaction that could exacerbate diseases when taken with Prednisone and Prednisone may cause a moderate interaction that cou... |
DB11714 | DB11988 | 1,316 | 270 | [
"DDInter610",
"DDInter1321"
] | Durvalumab | Ocrelizumab | Durvalumab is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody and a novel immune-checkpoint inhibitor for cancer treatment. Produced by recombinant DNA technology in Chinese Hamster Ovary (CHO) cell suspension culture, durvalumab is a programmed death-ligand 1 (PD-L1) blocking antibody that works to promote... | Ocrelizumab is a CD20-directed cytolytic antibody indicated for the treatment of patients with primary progressive or relapsing forms of multiple sclerosis (MS). It is a second-generation recombinant humanized monoclonal IgG1 antibody that selectively targets B-cells that express the CD20 antigen. Compared to non-human... | Moderate | 1 | [
[
[
1316,
24,
270
]
],
[
[
1316,
62,
1193
],
[
1193,
23,
270
]
],
[
[
1316,
24,
1019
],
[
1019,
24,
270
]
],
[
[
1316,
63,
713
],
[
713,
... | [
[
[
"Durvalumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
]
],
[
[
"Durvalumab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc gluconate"
],
[... | Durvalumab may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Ocrelizumab
Durvalumab may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort and ... |
DB00761 | DB01618 | 1,621 | 776 | [
"DDInter1497",
"DDInter1239"
] | Potassium chloride | Molindone | A white crystal or crystalline powder used as an electrolyte replenisher, in the treatment of hypokalemia, in buffer solutions, and in fertilizers and explosives. The FDA withdrew its approval for the use of all solid oral dosage form drug products containing potassium chloride that supply 100 mg or more of potassium p... | An indole derivative effective in schizophrenia and other psychoses and possibly useful in the treatment of the aggressive type of undersocialized conduct disorder. Molindone has much lower affinity for D2 receptors than most antipsychotic agents and has a relatively low affinity for D1 receptors. It has only low to mo... | Major | 2 | [
[
[
1621,
25,
776
]
],
[
[
1621,
21,
28680
],
[
28680,
60,
776
]
],
[
[
1621,
25,
100
],
[
100,
24,
776
]
],
[
[
1621,
64,
1442
],
[
1442,... | [
[
[
"Potassium chloride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Molindone"
]
],
[
[
"Potassium chloride",
"{u} (Compound) causes {v} (Side Effect)",
"Rash"
],
[
"Rash",
"{u} (Side Effect) is caused by {v} ... | Potassium chloride (Compound) causes Rash (Side Effect) and Rash (Side Effect) is caused by Molindone (Compound)
Potassium chloride may lead to a major life threatening interaction when taken with Brompheniramine and Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Molindo... |
DB01284 | DB11627 | 1,042 | 1,367 | [
"DDInter1782",
"DDInter860"
] | Tetracosactide | Hepatitis B Vaccine (Recombinant) | Tetracosactide (also known as Cosyntropin) is a synthetic peptide that is identical to the 24-amino acid segment (sequence: SYSMEHFRWGKPVGKKRRPVKVYP) at the N-terminal of adrenocorticotropic hormone. ACTH (1-24), a segment similar in all species, contains the biological activity that stimulates production of corticoste... | Hepatitis B Vaccine is an ingredient in the EMA-withdrawn product Quintanrix. It is marketed in Canada as Engerix B. It is also a part of Twinrix (Hep A/Hep B vaccine) available also in Canada. The hepatitis B virus induces a severe form of viral hepatitis. Other causative agents are hepatitis A virus, and the non-A, n... | Moderate | 1 | [
[
[
1042,
24,
1367
]
],
[
[
1042,
63,
1648
],
[
1648,
24,
1367
]
],
[
[
1042,
64,
1064
],
[
1064,
24,
1367
]
],
[
[
1042,
24,
259
],
[
259... | [
[
[
"Tetracosactide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis B Vaccine (Recombinant)"
]
],
[
[
"Tetracosactide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
... | Tetracosactide may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis B Vaccine (Recombinant)
Tetracosactide may lead to a major life threatening interaction when taken with Cla... |
DB00169 | DB01396 | 386 | 1,482 | [
"DDInter367",
"DDInter553"
] | Cholecalciferol | Digitoxin | Vitamin D, in general, is a secosteroid generated in the skin when 7-dehydrocholesterol located there interacts with ultraviolet irradiation - like that commonly found in sunlight. Both the endogenous form of vitamin D (that results from 7-dehydrocholesterol transformation), vitamin D3 (cholecalciferol), and the plant-... | A cardiac glycoside sometimes used in place of digoxin. It has a longer half-life than digoxin; toxic effects, which are similar to those of digoxin, are longer lasting. (From Martindale, The Extra Pharmacopoeia, 30th ed, p665) | Moderate | 1 | [
[
[
386,
24,
1482
]
],
[
[
386,
24,
1252
],
[
1252,
1,
1482
]
],
[
[
386,
6,
8374
],
[
8374,
45,
1482
]
],
[
[
386,
6,
2710
],
[
2710,
... | [
[
[
"Cholecalciferol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Digitoxin"
]
],
[
[
"Cholecalciferol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Digoxin"
],
... | Cholecalciferol may cause a moderate interaction that could exacerbate diseases when taken with Digoxin and Digoxin (Compound) resembles Digitoxin (Compound)
Cholecalciferol (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Digitoxin (Compound)
Cholecalciferol (Compound) binds CDC25A (Gene) and CDC25A (Gene)... |
DB08893 | DB11837 | 271 | 1,297 | [
"DDInter1229",
"DDInter1351"
] | Mirabegron | Osilodrostat | Mirabegron is a sympathomimetic beta-3 adrenergic receptor agonist used to relax the smooth muscle of the bladder in the treatment of urinary frequency and incontinence. It is unique amongst overactive bladder treatment options in that, unlike other treatments such as [solifenacin] and [darifenacin], it lacks significa... | Osilodrostat is an inhibitor of 11β-hydroxylase (also referred to as CYP11B1), the enzyme that catalyzes the final step in the biosynthesis of endogenous cortisol. It is used to lower circulating cortisol levels in the treatment of Cushing's disease, a disorder in which cortisol levels are chronically and supraphysiolo... | Minor | 0 | [
[
[
271,
23,
1297
]
],
[
[
271,
23,
1320
],
[
1320,
63,
1297
]
],
[
[
271,
62,
353
],
[
353,
24,
1297
]
],
[
[
271,
63,
401
],
[
401,
... | [
[
[
"Mirabegron",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Osilodrostat"
]
],
[
[
"Mirabegron",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Elagolix"
],
[
... | Mirabegron may cause a minor interaction that can limit clinical effects when taken with Elagolix and Elagolix may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat
Mirabegron may cause a minor interaction that can limit clinical effects when taken with Griseofulvin and Griseofulv... |
DB00207 | DB11718 | 1,570 | 927 | [
"DDInter157",
"DDInter640"
] | Azithromycin | Encorafenib | Azithromycin is a broad-spectrum macrolide antibiotic with a long half-life and a high degree of tissue penetration. It was initially approved by the FDA in 1991. It is primarily used for the treatment of respiratory, enteric and genitourinary infections and may be used instead of other macrolides for some sexually tra... | Encorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and ... | Moderate | 1 | [
[
[
1570,
24,
927
]
],
[
[
1570,
23,
112
],
[
112,
23,
927
]
],
[
[
1570,
24,
720
],
[
720,
24,
927
]
],
[
[
1570,
24,
484
],
[
484,
... | [
[
[
"Azithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
]
],
[
[
"Azithromycin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
... | Azithromycin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Encorafenib
Azithromycin may cause a moderate interaction that could exacerbate diseases when taken with Mineral oil an... |
DB00834 | DB01268 | 932 | 1,151 | [
"DDInter1215",
"DDInter1731"
] | Mifepristone | Sunitinib | Mifepristone is a progestational and glucocorticoid hormone antagonist. Its inhibition of progesterone induces bleeding during the luteal phase and in early pregnancy by releasing endogenous prostaglandins from the endometrium or decidua. As a glucocorticoid receptor antagonist, the drug has been used to treat hypercor... | Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally av... | Major | 2 | [
[
[
932,
25,
1151
]
],
[
[
932,
6,
4973
],
[
4973,
45,
1151
]
],
[
[
932,
7,
7153
],
[
7153,
46,
1151
]
],
[
[
932,
18,
3965
],
[
3965,
... | [
[
[
"Mifepristone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sunitinib"
]
],
[
[
"Mifepristone",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Suniti... | Mifepristone (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Sunitinib (Compound)
Mifepristone (Compound) upregulates PCK2 (Gene) and PCK2 (Gene) is upregulated by Sunitinib (Compound)
Mifepristone (Compound) downregulates MRPS2 (Gene) and MRPS2 (Gene) is downregulated by Sunitinib (Compound)
Mifepristone (C... |
DB04865 | DB13985 | 4 | 546 | [
"DDInter1335",
"DDInter1108"
] | Omacetaxine mepesuccinate | Lutetium Lu 177 dotatate | Omacetaxine mepesuccinate (formerly known as HHT or Homoharringtonine), is a cephalotaxine ester and protein synthesis inhibitor with established clinical activity as a single agent in hematological malignancies. Omacetaxine mepesuccinate is synthesized from cephalotaxine, which is an extract from the leaves of the pla... | A 177Lu-labeled somatostatin analog peptide, Lutetium Lu 177 dotatate belongs to an emerging form of treatments called Peptide Receptor Radionuclide Therapy (PRRT), which involves targeting tumours with molecules carrying radioactive particles that bind to specific receptors expressed by the tumour. Lutetium Lu 177 dot... | Moderate | 1 | [
[
[
4,
24,
546
]
],
[
[
4,
63,
66
],
[
66,
24,
546
]
],
[
[
4,
24,
1683
],
[
1683,
24,
546
]
],
[
[
4,
64,
1057
],
[
1057,
25,
... | [
[
[
"Omacetaxine mepesuccinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lutetium Lu 177 dotatate"
]
],
[
[
"Omacetaxine mepesuccinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken w... | Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab and Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Lutetium Lu 177 dotatate
Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate di... |
DB00182 | DB01069 | 80 | 401 | [
"DDInter84",
"DDInter1533"
] | Amphetamine | Promethazine | Amphetamine, a compound discovered over 100 years ago, is one of the more restricted controlled drugs. It was previously used for a large variety of conditions and this changed until this point where its use is highly restricted. Amphetamine, with the chemical formula alpha-methylphenethylamine, was discovered in 1910 ... | Promethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946. Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.[A189907,A1... | Moderate | 1 | [
[
[
80,
24,
401
]
],
[
[
80,
24,
1264
],
[
1264,
63,
401
]
],
[
[
80,
40,
939
],
[
939,
24,
401
]
],
[
[
80,
24,
104
],
[
104,
24,
... | [
[
[
"Amphetamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
]
],
[
[
"Amphetamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
[
... | Amphetamine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Promethazine
Amphetamine (Compound) resembles Benzphetamine (Compound) and Benzphetamine may cause a moderate interaction that c... |
DB00531 | DB08908 | 450 | 713 | [
"DDInter456",
"DDInter564"
] | Cyclophosphamide | Dimethyl fumarate | Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause steril... | Dimethyl fumarate is an agent indicated for the treatment of relapsing forms of multiple sclerosis.[A253942,L43752] The mechanism of action of dimethyl fumarate in multiple sclerosis is not well understood. It is thought to involve dimethyl fumarate degradation to its active metabolite monomethyl fumarate (MMF) then MM... | Moderate | 1 | [
[
[
450,
24,
713
]
],
[
[
450,
24,
4
],
[
4,
24,
713
]
],
[
[
450,
63,
552
],
[
552,
24,
713
]
],
[
[
450,
24,
270
],
[
270,
63,
... | [
[
[
"Cyclophosphamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dimethyl fumarate"
]
],
[
[
"Cyclophosphamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omacetax... | Cyclophosphamide may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Dimethyl fumarate
Cyclophosphamide may cause a moderate interaction that could exacerba... |
DB00382 | DB00694 | 62 | 51 | [
"DDInter1734",
"DDInter485"
] | Tacrine | Daunorubicin | A centerally active cholinesterase inhibitor that has been used to counter the effects of muscle relaxants, as a respiratory stimulant, and in the treatment of Alzheimer's disease and other central nervous system disorders. Tacrine has been discontinued for the United States market. | A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of leukemia and other neoplasms. | Moderate | 1 | [
[
[
62,
24,
51
]
],
[
[
62,
24,
112
],
[
112,
62,
51
]
],
[
[
62,
23,
1001
],
[
1001,
63,
51
]
],
[
[
62,
24,
477
],
[
477,
63,
... | [
[
[
"Tacrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Daunorubicin"
]
],
[
[
"Tacrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
[
... | Tacrine may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Daunorubicin
Tacrine may cause a minor interaction that can limit clinical effects when taken with Mechlorethamine and Mec... |
DB00808 | DB01067 | 1,605 | 959 | [
"DDInter916",
"DDInter826"
] | Indapamide | Glipizide | The most significant modifiable risk factor for cardiovascular disease and the most prominent contributor to all-cause mortality is hypertension. Characterized by an office blood pressure of ≥140/90, hypertension is pervasive and impacts an estimated 25% of adults globally. Treatment for hypertension should include a n... | Glipizide is an oral hypoglycemic agent in the second-generation sulfonylurea drug class that is used to control blood sugar levels in patients with type 2 diabetes mellitus. It was first introduced in 1984 and is available in various countries including Canada and the U.S. According to the 2018 Clinical Practice Guide... | Moderate | 1 | [
[
[
1605,
24,
959
]
],
[
[
1605,
63,
245
],
[
245,
40,
959
]
],
[
[
1605,
24,
1411
],
[
1411,
1,
959
]
],
[
[
1605,
6,
8374
],
[
8374,
... | [
[
[
"Indapamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
]
],
[
[
"Indapamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
],
[
... | Indapamide may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride (Compound) resembles Glipizide (Compound)
Indapamide may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide (Compound) resembles Glipizide (Compound... |
DB01076 | DB11989 | 700 | 1,434 | [
"DDInter133",
"DDInter183"
] | Atorvastatin | Benznidazole | Atorvastatin (Lipitor®), is a lipid-lowering drug included in the statin class of medications. By inhibiting the endogenous production of cholesterol in the liver, statins lower abnormal cholesterol and lipid levels, and ultimately reduce the risk of cardiovascular disease. More specifically, statin medications competi... | Benznidazole was granted accelerated approval for the treatment of Chagas disease in children 2-12 years of age by the FDA on August 29, 2017. It is the first treatment made available in the United States for Chagas disease. | Moderate | 1 | [
[
[
700,
24,
1434
]
],
[
[
700,
40,
788
],
[
788,
24,
1434
]
],
[
[
700,
24,
375
],
[
375,
24,
1434
]
],
[
[
700,
24,
148
],
[
148,
... | [
[
[
"Atorvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Benznidazole"
]
],
[
[
"Atorvastatin",
"{u} (Compound) resembles {v} (Compound)",
"Pitavastatin"
],
[
"Pitavastatin",
"{u} may cause... | Atorvastatin (Compound) resembles Pitavastatin (Compound) and Pitavastatin may cause a moderate interaction that could exacerbate diseases when taken with Benznidazole
Atorvastatin may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol and Certolizumab pegol may cause a moder... |
DB04855 | DB06626 | 540 | 263 | [
"DDInter602",
"DDInter147"
] | Dronedarone | Axitinib | Dronedarone is a Class III antiarrhythmic drug that works to restore the normal sinus rhythm in patients with paroxysmal or persistent atrial fibrillation. Atrial fibrillation is a common sustained arrhythmia where the treatment primarily focuses on stroke prevention and symptom management. It is managed by rate contro... | Axitinib is a second generation tyrosine kinase inhibitor that works by selectively inhibiting vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3). Through this mechanism of action, axitinib blocks angiogenesis, tumour growth and metastases. It is reported to exhibit potency that is 50-450 times hi... | Moderate | 1 | [
[
[
540,
24,
263
]
],
[
[
540,
63,
752
],
[
752,
23,
263
]
],
[
[
540,
24,
286
],
[
286,
62,
263
]
],
[
[
540,
64,
322
],
[
322,
24,... | [
[
[
"Dronedarone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Axitinib"
]
],
[
[
"Dronedarone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cimetidine"
],
[
... | Dronedarone may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine and Cimetidine may cause a minor interaction that can limit clinical effects when taken with Axitinib
Dronedarone may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide and... |
DB00009 | DB00374 | 1,271 | 1,061 | [
"DDInter56",
"DDInter1852"
] | Alteplase | Treprostinil | Alteplase is a recombinant tissue plasminogen activator (rt-PA) used as a thrombolytic agent. It cleaves plasminogen to form plasmin, an enzyme involved in the degradation of fibrin clots. In the absence of fibrin, the alteplase-mediated conversion of plasminogen is limited, thanks to the high affinity between alteplas... | Treprostinil is a stable tricyclic analogue of prostacyclin that promotes the vasodilation of pulmonary and systemic arterial vascular beds and the inhibition of platelet aggregation.[L41855,L41860,L41865] It reduces symptoms in patients with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated w... | Moderate | 1 | [
[
[
1271,
24,
1061
]
],
[
[
1271,
24,
885
],
[
885,
40,
1061
]
],
[
[
1271,
23,
539
],
[
539,
62,
1061
]
],
[
[
1271,
24,
914
],
[
914,
... | [
[
[
"Alteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Treprostinil"
]
],
[
[
"Alteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epoprostenol"
],
[
... | Alteplase may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol and Epoprostenol (Compound) resembles Treprostinil (Compound)
Alteplase may cause a minor interaction that can limit clinical effects when taken with Capsicum and Capsicum may cause a minor interaction that can limit ... |
DB00865 | DB01278 | 939 | 1,021 | [
"DDInter187",
"DDInter1506"
] | Benzphetamine | Pramlintide | A sympathomimetic agent with properties similar to dextroamphetamine. It is used in the treatment of obesity. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1222) | Pramlintide is a relatively new adjunct treatment for diabetes (both type 1 and 2), developed by Amylin Pharmaceuticals. It is derived from amylin, a hormone that is released into the bloodstream, in a similar pattern as insulin, after a meal. Like insulin, amylin is deficient in individuals with diabetes. | Moderate | 1 | [
[
[
939,
24,
1021
]
],
[
[
939,
64,
1466
],
[
1466,
24,
1021
]
],
[
[
939,
24,
22
],
[
22,
63,
1021
]
],
[
[
939,
63,
1144
],
[
1144,
... | [
[
[
"Benzphetamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pramlintide"
]
],
[
[
"Benzphetamine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Phenylpropanolamine"
],
[
... | Benzphetamine may lead to a major life threatening interaction when taken with Phenylpropanolamine and Phenylpropanolamine may cause a moderate interaction that could exacerbate diseases when taken with Pramlintide
Benzphetamine may cause a moderate interaction that could exacerbate diseases when taken with Ephedrine a... |
DB00945 | DB01165 | 1,479 | 1,539 | [
"DDInter20",
"DDInter1325"
] | Acetylsalicylic acid | Ofloxacin | Also known as _Aspirin_, acetylsalicylic acid (ASA) is a commonly used drug for the treatment of pain and fever due to various causes. Acetylsalicylic acid has both anti-inflammatory and antipyretic effects. This drug also inhibits platelet aggregation and is used in the prevention of blood clots stroke, and myocardial... | A synthetic fluoroquinolone (fluoroquinolones) antibacterial agent that inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication. | Moderate | 1 | [
[
[
1479,
24,
1539
]
],
[
[
1479,
63,
1467
],
[
1467,
1,
1539
]
],
[
[
1479,
24,
945
],
[
945,
40,
1539
]
],
[
[
1479,
24,
739
],
[
739,
... | [
[
[
"Acetylsalicylic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ofloxacin"
]
],
[
[
"Acetylsalicylic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enoxacin... | Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Enoxacin and Enoxacin (Compound) resembles Ofloxacin (Compound)
Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Sparfloxacin and Sparfloxacin (Compound) resembles Ofl... |
DB00206 | DB01240 | 1,245 | 885 | [
"DDInter1582",
"DDInter657"
] | Reserpine | Epoprostenol | An alkaloid found in the roots of Rauwolfia serpentina and R. vomitoria. Reserpine inhibits the uptake of norepinephrine into storage vesicles resulting in depletion of catecholamines and serotonin from central and peripheral axon terminals. It has been used as an antihypertensive and an antipsychotic as well as a rese... | A prostaglandin that is a powerful vasodilator and inhibits platelet aggregation. It is biosynthesized enzymatically from prostaglandin endoperoxides in human vascular tissue. The sodium salt has been also used to treat primary pulmonary hypertension. | Moderate | 1 | [
[
[
1245,
24,
885
]
],
[
[
1245,
24,
1061
],
[
1061,
1,
885
]
],
[
[
1245,
21,
28642
],
[
28642,
60,
885
]
],
[
[
1245,
24,
1450
],
[
1450... | [
[
[
"Reserpine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epoprostenol"
]
],
[
[
"Reserpine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Treprostinil"
],
[
... | Reserpine may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil (Compound) resembles Epoprostenol (Compound)
Reserpine (Compound) causes Shock (Side Effect) and Shock (Side Effect) is caused by Epoprostenol (Compound)
Reserpine may cause a moderate interaction tha... |
DB00252 | DB08882 | 362 | 1,281 | [
"DDInter1460",
"DDInter1070"
] | Phenytoin | Linagliptin | Phenytoin is classified as a hydantoin derivative and despite its narrow therapeutic index, it is one of the most commonly used anticonvulsants.[A33595,A188832,A189219] Since it's introduction about 80 years ago, phenytoin has not only been established as an effective anti-epileptic, but has also been investigated for ... | Linagliptin is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes . Linagliptin differs from other DPP-4 inhibitors in that it has a non-linear pharmacokinetic profile, is not primarily eliminated by the renal system, and obeys concentration dependant protein binding. Linagliptin ... | Moderate | 1 | [
[
[
362,
24,
1281
]
],
[
[
362,
24,
1002
],
[
1002,
1,
1281
]
],
[
[
362,
6,
8374
],
[
8374,
45,
1281
]
],
[
[
362,
21,
28762
],
[
28762,
... | [
[
[
"Phenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Linagliptin"
]
],
[
[
"Phenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alogliptin"
],
[
... | Phenytoin may cause a moderate interaction that could exacerbate diseases when taken with Alogliptin and Alogliptin (Compound) resembles Linagliptin (Compound)
Phenytoin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Linagliptin (Compound)
Phenytoin (Compound) causes Headache (Side Effect) and Headache (S... |
DB01229 | DB06595 | 973 | 1,491 | [
"DDInter1378",
"DDInter1214"
] | Paclitaxel (protein-bound) | Midostaurin | Paclitaxel can cause developmental toxicity, female reproductive toxicity and male reproductive toxicity according to state or federal government labeling requirements. | Midostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3. It was initially characterized as a potential broad-spectrum antineoplastic agent, with activity toward diverse solid and hem... | Moderate | 1 | [
[
[
973,
24,
1491
]
],
[
[
973,
63,
112
],
[
112,
23,
1491
]
],
[
[
973,
63,
289
],
[
289,
24,
1491
]
],
[
[
973,
24,
1017
],
[
1017,
... | [
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Midostaurin"
]
],
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
... | Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin
Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Midostaurin
Pacl... |
DB00436 | DB01169 | 323 | 57 | [
"DDInter179",
"DDInter120"
] | Bendroflumethiazide | Arsenic trioxide | A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. It has been used in the treatment of familial hyperkalemia, hypertension, edema, and urinary tract disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p810) | Arsenic trioxide is a chemotherapeutic agent of idiopathic function used to treat leukemia that is unresponsive to first line agents. It is suspected that arsenic trisulfide induces cancer cells to undergo apoptosis. In general, arsenic is known to be a naturally toxic substance capable of eliciting a variety of danger... | Major | 2 | [
[
[
323,
25,
57
]
],
[
[
323,
24,
603
],
[
603,
63,
57
]
],
[
[
323,
24,
480
],
[
480,
24,
57
]
],
[
[
323,
24,
167
],
[
167,
25,
... | [
[
[
"Bendroflumethiazide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Arsenic trioxide"
]
],
[
[
"Bendroflumethiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium citrate"... | Bendroflumethiazide may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate and Magnesium citrate may cause a moderate interaction that could exacerbate diseases when taken with Arsenic trioxide
Bendroflumethiazide may cause a moderate interaction that could exacerbate diseases... |
DB00434 | DB00802 | 13 | 1,322 | [
"DDInter459",
"DDInter43"
] | Cyproheptadine | Alfentanil | Cyproheptadine is a potent competitive antagonist of both serotonin and histamine receptors. It is used primarily to treat allergic symptoms, though it is perhaps more notable for its use in appetite stimulation and its off-label use in the treatment of serotonin syndrome. | A short-acting opioid anesthetic and analgesic derivative of fentanyl. It produces an early peak analgesic effect and fast recovery of consciousness. Alfentanil is effective as an anesthetic during surgery, for supplementation of analgesia during surgical procedures, and as an analgesic for critically ill patients. | Moderate | 1 | [
[
[
13,
24,
1322
]
],
[
[
13,
24,
411
],
[
411,
1,
1322
]
],
[
[
13,
21,
29118
],
[
29118,
60,
1322
]
],
[
[
13,
24,
1219
],
[
1219,
... | [
[
[
"Cyproheptadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alfentanil"
]
],
[
[
"Cyproheptadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Remifentanil"
]... | Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Remifentanil and Remifentanil (Compound) resembles Alfentanil (Compound)
Cyproheptadine (Compound) causes Tachycardia (Side Effect) and Tachycardia (Side Effect) is caused by Alfentanil (Compound)
Cyproheptadine may cause a m... |
DB14975 | DB15091 | 988 | 676 | [
"DDInter1949",
"DDInter1901"
] | Voxelotor | Upadacitinib | Voxelotor is a novel hemoglobin S polymerization inhibitor for the treatment of sickle cell disease. This is a genetically inherited condition most prevalent in the Middle East, Africa, and certain parts of India. Sickle cell disease can lead to excruciating pain, stroke, infection, and various other complications aris... | Upadacitinib is an oral Janus kinase (JAK)1-selective inhibitor and a disease-modifying antirheumatic drug (DMARD) used in the treatment of rheumatoid arthritis to slow down disease progression. Rheumatoid arthritis is a chronic autoimmune inflammatory disease affecting the peripheral joints. It is characterized by syn... | Moderate | 1 | [
[
[
988,
24,
676
]
],
[
[
988,
63,
283
],
[
283,
24,
676
]
],
[
[
988,
64,
600
],
[
600,
24,
676
]
],
[
[
988,
63,
891
],
[
891,
25,... | [
[
[
"Voxelotor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Upadacitinib"
]
],
[
[
"Voxelotor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
],
[
... | Voxelotor may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Upadacitinib
Voxelotor may lead to a major life threatening interaction when taken with Fluconazole and Fluconazole may caus... |
DB01229 | DB06168 | 973 | 1,531 | [
"DDInter1377",
"DDInter281"
] | Paclitaxel | Canakinumab | Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intr... | Canakinumab is a recombinant, human anti-human-IL-1β monoclonal antibody that belongs to the IgG1/κ isotype subclass. It is expressed in a murine Sp2/0-Ag14 cell line and comprised of two 447- (or 448-) residue heavy chains and two 214-residue light chains, with a molecular mass of 145157 Daltons when deglycosylated. B... | Moderate | 1 | [
[
[
973,
24,
1531
]
],
[
[
973,
63,
1461
],
[
1461,
23,
1531
]
],
[
[
973,
24,
1270
],
[
1270,
63,
1531
]
],
[
[
973,
24,
1213
],
[
1213,
... | [
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canakinumab"
]
],
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
... | Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Canakinumab
Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified prot... |
DB06176 | DB12035 | 1,342 | 943 | [
"DDInter1616",
"DDInter1641"
] | Romidepsin | Sarecycline | Romidepsin is a selective inhibitor of histone deacetylase, approved in the US in 2009 for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy. | Sarecycline is a semi-synthetic derivative of tetracycline that was initially discovered by Paratek Pharmaceuticals from Boston, MA but then licensed to Warner Chilcott of Rockaway, NJ in July of 2007 . After completing various phase-II and phase-III trials demonstrating its effectiveness in treating moderate to severe... | Moderate | 1 | [
[
[
1342,
24,
943
]
],
[
[
1342,
63,
1181
],
[
1181,
24,
943
]
],
[
[
1342,
24,
1456
],
[
1456,
24,
943
]
],
[
[
1342,
24,
1619
],
[
1619,... | [
[
[
"Romidepsin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sarecycline"
]
],
[
[
"Romidepsin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Terfenadine"
],
[
... | Romidepsin may cause a moderate interaction that could exacerbate diseases when taken with Terfenadine and Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Sarecycline
Romidepsin may cause a moderate interaction that could exacerbate diseases when taken with Venetoclax and Ven... |
DB00621 | DB00741 | 1,026 | 167 | [
"DDInter1357",
"DDInter885"
] | Oxandrolone | Hydrocortisone | A synthetic hormone with anabolic and androgenic properties. | Hydrocortisone, or cortisol, is a glucocorticoid secreted by the adrenal cortex. Hydrocortisone is used to treat immune, inflammatory, and neoplastic conditions.[L10529,L10532,L10535,L10538,L7772,L7321] It was discovered in the 1930s by Edward Kendall and named Compound F, or 17-hydroxycorticosterone. Hydrocortisone wa... | Moderate | 1 | [
[
[
1026,
24,
167
]
],
[
[
1026,
40,
11385
],
[
11385,
40,
167
]
],
[
[
1026,
24,
1220
],
[
1220,
40,
167
]
],
[
[
1026,
40,
443
],
[
443,... | [
[
[
"Oxandrolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydrocortisone"
]
],
[
[
"Oxandrolone",
"{u} (Compound) resembles {v} (Compound)",
"Formestane"
],
[
"Formestane",
"{u} (Compound) re... | Oxandrolone (Compound) resembles Formestane (Compound) and Formestane (Compound) resembles Hydrocortisone (Compound)
Oxandrolone may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone (Compound) resembles Hydrocortisone (Compound)
Oxandrolone (Compound) resembles... |
DB00055 | DB06209 | 834 | 256 | [
"DDInter605",
"DDInter1508"
] | Drotrecogin alfa | Prasugrel | Drotrecogin alfa is activated human protein C that is synthesized by recombinant DNA technology. It is a glycoprotein of approximately 55 kilodalton molecular weight, consisting of a heavy chain and a light chain linked by a disulfide bond. Drotrecogin alfa was withdrawn from the market after a major study indicated th... | Prasugrel, a thienopyridine derivative, is a platelet activation and aggregation inhibitor structurally and pharmacologically related to clopidogrel and ticlopidine. Similar to clopidogrel, prasugrel is a prodrug that requires enzymatic transformation in the liver to its active metabolite, R-138727. R-138727 irreversib... | Major | 2 | [
[
[
834,
25,
256
]
],
[
[
834,
23,
944
],
[
944,
62,
256
]
],
[
[
834,
24,
901
],
[
901,
24,
256
]
],
[
[
834,
24,
1427
],
[
1427,
6... | [
[
[
"Drotrecogin alfa",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Prasugrel"
]
],
[
[
"Drotrecogin alfa",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Chamomile"
],
[
"Ch... | Drotrecogin alfa may cause a minor interaction that can limit clinical effects when taken with Chamomile and Chamomile may cause a minor interaction that can limit clinical effects when taken with Prasugrel
Drotrecogin alfa may cause a moderate interaction that could exacerbate diseases when taken with Milnacipran and ... |
DB00549 | DB00731 | 522 | 1,144 | [
"DDInter1955",
"DDInter1269"
] | Zafirlukast | Nateglinide | Zafirlukast is an oral leukotriene receptor antagonist (LTRA) for the maintenance treatment of asthma, often used in conjunction with an inhaled steroid and/or long-acting bronchodilator. It is available as a tablet and is usually dosed twice daily. Another leukotriene receptor antagonist is montelukast (Singulair), wh... | Nateglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Nateglinide is an amino acid derivative that ... | Moderate | 1 | [
[
[
522,
24,
1144
]
],
[
[
522,
63,
168
],
[
168,
24,
1144
]
],
[
[
522,
6,
6017
],
[
6017,
45,
1144
]
],
[
[
522,
21,
28787
],
[
28787,
... | [
[
[
"Zafirlukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nateglinide"
]
],
[
[
"Zafirlukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
[... | Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide
Zafirlukast (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Nateglinide (Compound)
Zafirlukast (C... |
DB00261 | DB00738 | 702 | 485 | [
"DDInter93",
"DDInter1420"
] | Anagrelide | Pentamidine | Anagrelide is a platelet-reducing agent used to lower dangerously elevated platelet levels (i.e. to treat thrombocythemia) in patients with myeloproliferative neoplasms. It is an oral imidazoquinazoline that was first approved for use in the US in 1997. It appears to carry a better response rate than other thrombocythe... | Antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of pneumocystis pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other toxic effects. | Major | 2 | [
[
[
702,
25,
485
]
],
[
[
702,
6,
7950
],
[
7950,
45,
485
]
],
[
[
702,
18,
4071
],
[
4071,
57,
485
]
],
[
[
702,
21,
28981
],
[
28981,
... | [
[
[
"Anagrelide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pentamidine"
]
],
[
[
"Anagrelide",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compound)",
"Pentam... | Anagrelide (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Pentamidine (Compound)
Anagrelide (Compound) downregulates PNP (Gene) and PNP (Gene) is downregulated by Pentamidine (Compound)
Anagrelide (Compound) causes Renal impairment (Side Effect) and Renal impairment (Side Effect) is caused by Pentamidine ... |
DB00694 | DB01042 | 51 | 1,307 | [
"DDInter485",
"DDInter1144"
] | Daunorubicin | Melphalan | A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of leukemia and other neoplasms. | Melphalan is a nitrogen mustard or bischloroethylamine type alkylating agent. It was first synthesized in the early 1950s by substituting L-phenylalanine for the methyl group on nitrogen mustard.[A261150, A261155] Melphalan is used in the treatment of multiple myeloma and ovarian carcinoma. It is also used for high-con... | Moderate | 1 | [
[
[
51,
24,
1307
]
],
[
[
51,
5,
11555
],
[
11555,
44,
1307
]
],
[
[
51,
18,
10635
],
[
10635,
46,
1307
]
],
[
[
51,
21,
29232
],
[
29232,... | [
[
[
"Daunorubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Melphalan"
]
],
[
[
"Daunorubicin",
"{u} (Compound) treats {v} (Disease)",
"hematologic cancer"
],
[
"hematologic cancer",
"{u} (Dis... | Daunorubicin (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Melphalan (Compound)
Daunorubicin (Compound) downregulates BLCAP (Gene) and BLCAP (Gene) is upregulated by Melphalan (Compound)
Daunorubicin (Compound) causes Urticaria (Side Effect) and Urticaria (Side Effect) is... |
DB00743 | DB01136 | 808 | 772 | [
"DDInter792",
"DDInter305"
] | Gadobenic acid | Carvedilol | Gadobenic acid, usually available in the salt form gadobenate dimeglumine, is a linear MRI gadolinium-based contrast agent (GBCA) used primarily for MR imaging of the liver. It differs from other GBCAs due to the benzene ring that confers weak protein binding, thus leading to an increased R1 and R2 relaxivity. As gadob... | Carvedilol is a racemic mixture where the S(-) enantiomer is both a beta and alpha-1 adrenoceptor blocker, and the R(+) enantiomer is an alpha-1 adrenoceptor blocker.[L7889,L7892] It is currently used to treat heart failure, left ventricular dysfunction, and hypertension.[L7889,L7892] The dual action of carvedilol is a... | Moderate | 1 | [
[
[
808,
24,
772
]
],
[
[
808,
21,
29224
],
[
29224,
60,
772
]
],
[
[
808,
24,
278
],
[
278,
63,
772
]
],
[
[
808,
1,
457
],
[
457,
... | [
[
[
"Gadobenic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carvedilol"
]
],
[
[
"Gadobenic acid",
"{u} (Compound) causes {v} (Side Effect)",
"Rash erythematous"
],
[
"Rash erythematous",
"{... | Gadobenic acid (Compound) causes Rash erythematous (Side Effect) and Rash erythematous (Side Effect) is caused by Carvedilol (Compound)
Gadobenic acid may cause a moderate interaction that could exacerbate diseases when taken with Iopodic acid and Iopodic acid may cause a moderate interaction that could exacerbate dise... |
DB00551 | DB05679 | 1,660 | 1,683 | [
"DDInter17",
"DDInter1907"
] | Acetohydroxamic acid | Ustekinumab | Acetohydroxamic Acid, a synthetic drug derived from hydroxylamine and ethyl acetate, is similar in structure to urea. In the urine, it acts as an antagonist of the bacterial enzyme urease. Acetohydroxamic Acid has no direct antimicrobial action and does not acidify urine directly. It is used, in addition to antibiotics... | Ustekinumab is a human immunoglobulin (Ig) G1 kappa monoclonal antibody directed against interleukin(IL)-12 and IL-23, which are cytokines that are involved in immune and inflammatory responses. It was generated via recombinant human IL-12 immunization of human Ig (hu-Ig) transgenic mice. It is a targeted biologic dise... | Moderate | 1 | [
[
[
1660,
24,
1683
]
],
[
[
1660,
24,
4
],
[
4,
24,
1683
]
],
[
[
1660,
24,
270
],
[
270,
63,
1683
]
],
[
[
1660,
63,
599
],
[
599,
... | [
[
[
"Acetohydroxamic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
]
],
[
[
"Acetohydroxamic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omacet... | Acetohydroxamic acid may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab
Acetohydroxamic acid may cause a moderate interaction that could exacer... |
DB01033 | DB10429 | 328 | 200 | [
"DDInter1156",
"DDInter282"
] | Mercaptopurine | Candida albicans | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | Candida albicans is a fungus which can provoke allergic reactions. Candida albicans is used in allergenic testing. | Moderate | 1 | [
[
[
328,
24,
200
]
],
[
[
328,
24,
1683
],
[
1683,
24,
200
]
],
[
[
328,
25,
976
],
[
976,
24,
200
]
],
[
[
328,
63,
869
],
[
869,
2... | [
[
[
"Mercaptopurine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Candida albicans"
]
],
[
[
"Mercaptopurine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
... | Mercaptopurine may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab and Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans
Mercaptopurine may lead to a major life threatening interaction when taken with Tofacitinib and Tofa... |
DB00959 | DB11866 | 1,486 | 1,068 | [
"DDInter1191",
"DDInter1618"
] | Methylprednisolone | Romosozumab | Methylprednisolone is a [prednisolone] derivative glucocorticoid with higher potency than [prednisone]. It was first described in the literature in the late 1950s.[A188811,A188814] Methylprednisolone was granted FDA approval on 24 October 1957. In the outbreak of COVID-19, low dose methylprednisolone-based therapy was ... | Romosozumab is a humanized monoclonal antibody indicated for the treatment of osteoperosis in postmenopausal women at high risk of fracture and patients who have failed in other treatments or are intolerant to other osteoperosis therapies. Romosozumab prevents bone resorption and induces the formation of bone though it... | Moderate | 1 | [
[
[
1486,
24,
1068
]
],
[
[
1486,
25,
770
],
[
770,
24,
1068
]
],
[
[
1486,
40,
167
],
[
167,
24,
1068
]
],
[
[
1486,
63,
1419
],
[
1419,
... | [
[
[
"Methylprednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Romosozumab"
]
],
[
[
"Methylprednisolone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thalidomide"
],
[... | Methylprednisolone may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Romosozumab
Methylprednisolone (Compound) resembles Hydrocortisone (Compound) and Hydrocortisone may cause a moderate interactio... |
DB00001 | DB06228 | 1,578 | 792 | [
"DDInter1037",
"DDInter1609"
] | Lepirudin | Rivaroxaban | Lepirudin is a recombinant hirudin formed by 65 amino acids that acts as a highly specific and direct thrombin inhibitor.[L41539,L41569] Natural hirudin is an endogenous anticoagulant found in _Hirudo medicinalis_ leeches. Lepirudin is produced in yeast cells and is identical to natural hirudin except for the absence o... | Rivaroxaban is an anticoagulant and the first orally active direct factor Xa inhibitor. Unlike warfarin, routine lab monitoring of INR is not necessary. However there is no antidote available in the event of a major bleed. Only the 10 mg tablet can be taken without regard to food. The 15 mg and 20 mg tablet should be t... | Major | 2 | [
[
[
1578,
25,
792
]
],
[
[
1578,
23,
944
],
[
944,
62,
792
]
],
[
[
1578,
24,
901
],
[
901,
24,
792
]
],
[
[
1578,
24,
738
],
[
738,
... | [
[
[
"Lepirudin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rivaroxaban"
]
],
[
[
"Lepirudin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Chamomile"
],
[
"Chamomile",
... | Lepirudin may cause a minor interaction that can limit clinical effects when taken with Chamomile and Chamomile may cause a minor interaction that can limit clinical effects when taken with Rivaroxaban
Lepirudin may cause a moderate interaction that could exacerbate diseases when taken with Milnacipran and Milnacipran ... |
DB01234 | DB12010 | 1,220 | 214 | [
"DDInter513",
"DDInter785"
] | Dexamethasone | Fostamatinib | Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like [... | Fostamatinib has been investigated for the treatment and basic science of Rheumatoid Arthritis and Immune Thrombocytopenic Purpura (ITP). It was approved on April 17, 2018, under the trade name Tavalisse for use in ITP [L2644, FDA Label]. Fostamatinib has also been granted orphan drug status by the FDA . Recently, fost... | Moderate | 1 | [
[
[
1220,
24,
214
]
],
[
[
1220,
25,
976
],
[
976,
24,
214
]
],
[
[
1220,
63,
1428
],
[
1428,
24,
214
]
],
[
[
1220,
24,
861
],
[
861,
... | [
[
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Dexamethasone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
],
[
"T... | Dexamethasone may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Isradipine and Isradipine ... |
DB10583 | DB12267 | 949 | 1,476 | [
"DDInter415",
"DDInter233"
] | Clostridium tetani toxoid antigen (formaldehyde inactivated) | Brigatinib | Clostridium tetani toxoid antigen (formaldehyde inactivated) is a vaccine for intramuscular injection. It is used for active immunization of children 7 years of age or older, and adults, for prevention of tetanus. The toxoid in the Clostridium tetani culture is grown and detoxified followed by purification via ammonium... | Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the E... | Moderate | 1 | [
[
[
949,
24,
1476
]
],
[
[
949,
63,
168
],
[
168,
23,
1476
]
],
[
[
949,
63,
629
],
[
629,
24,
1476
]
],
[
[
949,
24,
1456
],
[
1456,
... | [
[
[
"Clostridium tetani toxoid antigen (formaldehyde inactivated)",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Clostridium tetani toxoid antigen (formaldehyde inactivated)",
"{u} may cause a moderate... | Clostridium tetani toxoid antigen (formaldehyde inactivated) may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Brigatinib
Clostridium tetani toxoid antigen (formaldehyde inactivated) may... |
DB09080 | DB09083 | 144 | 880 | [
"DDInter1331",
"DDInter996"
] | Olodaterol | Ivabradine | Olodaterol is a novel, long-acting beta2-adrenergic agonist (LABA) that exerts its pharmacological effect by binding and activating beta2-adrenergic receptors located primarily in the lungs. Beta2-adrenergic receptors are membrane-bound receptors that are normally activated by endogenous epinephrine whose signalling, v... | Ivabradine is a novel heart rate lowering medicine for the symptomatic management of stable angina pectoralis and symptomatic chronic heart failure. Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus r... | Moderate | 1 | [
[
[
144,
24,
880
]
],
[
[
144,
63,
480
],
[
480,
24,
880
]
],
[
[
144,
24,
659
],
[
659,
24,
880
]
],
[
[
144,
63,
39
],
[
39,
25,
... | [
[
[
"Olodaterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivabradine"
]
],
[
[
"Olodaterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Formoterol"
],
[
... | Olodaterol may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Ivabradine
Olodaterol may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol and Vilant... |
DB00361 | DB00900 | 134 | 45 | [
"DDInter1939",
"DDInter544"
] | Vinorelbine | Didanosine | Vinorelbine is an anti-mitotic chemotherapy drug that is used in the treatment of several types of malignancies, including breast cancer and non-small cell lung cancer (NSCLC). It was initially approved in the USA in 1990's for the treatment of NSCLC. It is a third-generation vinca alkaloid. The introduction of third-g... | A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. Didanosine is a potent inhibitor of HIV replication, acting as a chain-termi... | Moderate | 1 | [
[
[
134,
24,
45
]
],
[
[
134,
21,
28709
],
[
28709,
60,
45
]
],
[
[
134,
24,
36
],
[
36,
63,
45
]
],
[
[
134,
25,
1292
],
[
1292,
63... | [
[
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Didanosine"
]
],
[
[
"Vinorelbine",
"{u} (Compound) causes {v} (Side Effect)",
"Decreased appetite"
],
[
"Decreased appetite",
"{u} (... | Vinorelbine (Compound) causes Decreased appetite (Side Effect) and Decreased appetite (Side Effect) is caused by Didanosine (Compound)
Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Eribulin and Eribulin may cause a moderate interaction that could exacerbate diseases when ta... |
DB00687 | DB14443 | 870 | 987 | [
"DDInter747",
"DDInter1931"
] | Fludrocortisone | Vibrio cholerae CVD 103-HgR strain live antigen | Fludrocortisone is a synthetic mineralocorticoid used in conjunction with [hydrocortisone] to replace missing endogenous corticosteroids in patients with adrenal insufficiency.[A187169,A187187] It is functionally similar to [aldosterone], the body's primary endogenous mineralocorticoid, and is structurally analogous to... | _Vibrio cholerae_ CVD 103-HgR strain live antigen is a component of Vaxchora, an oral vaccine for immunization against _Vibrio cholerae_ serogroup O1. Cholera is an acute bacterial disease of the small intestine caused by _Vibrio cholerae_, which is gram-negative bacteria. Two serogroups of _V. cholerae_, O1 and O139, ... | Moderate | 1 | [
[
[
870,
24,
987
]
],
[
[
870,
1,
1220
],
[
1220,
24,
987
]
],
[
[
870,
24,
351
],
[
351,
24,
987
]
],
[
[
870,
64,
581
],
[
581,
24... | [
[
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vibrio cholerae CVD 103-HgR strain live antigen"
]
],
[
[
"Fludrocortisone",
"{u} (Compound) resembles {v} (Compound)",
"Dexamethasone"
],
[
... | Fludrocortisone (Compound) resembles Dexamethasone (Compound) and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Vibrio cholerae CVD 103-HgR strain live antigen
Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and R... |
DB00108 | DB00848 | 1,066 | 281 | [
"DDInter1268",
"DDInter1044"
] | Natalizumab | Levamisole | Natalizumab is a recombinant humanized IgG4κ monoclonal antibody that binds to α4-integrin. While natalizumab was originally approved by the FDA to treat multiple sclerosis in 2004, it was withdrawn from the market following multiple reports of fatal progressive multifocal leukoencephalopathy (PML). In 2006, the FDA re... | Levamisole is an antihelminthic drug that was commonly used for the treatment of parasitic, viral, and bacterial infections. It was manufactured by _Janssen_ and first used in 1969 as an agent to treat worm infestations Levamisole was approved by the FDA in 1990 as an adjuvant treatment for colon cancer. Prior to this,... | Major | 2 | [
[
[
1066,
25,
281
]
],
[
[
1066,
64,
599
],
[
599,
24,
281
]
],
[
[
1066,
25,
1683
],
[
1683,
63,
281
]
],
[
[
1066,
24,
1136
],
[
1136,
... | [
[
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Levamisole"
]
],
[
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Alemtuzumab"
],
[
"Alemtuzumab",
"{... | Natalizumab may lead to a major life threatening interaction when taken with Alemtuzumab and Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Levamisole
Natalizumab may lead to a major life threatening interaction when taken with Ustekinumab and Ustekinumab may cause a moderat... |
DB00461 | DB08870 | 598 | 850 | [
"DDInter1254",
"DDInter228"
] | Nabumetone | Brentuximab vedotin | Nabumetone was originally developed as a non-acidic non-steroidal anti-inflammatory drug (NSAID).[label] It was thought to avoid trapping of the drug in the stomach by making it unable to dissociate into ions which was believed to reduce GI toxicity by limiting local action. While slightly reduced, possibly due to a de... | Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large-cell lymphoma. Brentuximab vedotin was initially approved... | Moderate | 1 | [
[
[
598,
24,
850
]
],
[
[
598,
24,
267
],
[
267,
24,
850
]
],
[
[
598,
63,
245
],
[
245,
24,
850
]
],
[
[
598,
25,
1468
],
[
1468,
6... | [
[
[
"Nabumetone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
]
],
[
[
"Nabumetone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naltrexone"
],... | Nabumetone may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone and Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Nabumetone may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride ... |
DB00526 | DB00640 | 1,555 | 1,585 | [
"DDInter1355",
"DDInter31"
] | Oxaliplatin | Adenosine | Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect. However, this leads to poorer water solubility, which was compensated by the addition of t... | The structure of adenosine was first described in 1931, though the vasodilating effects were not described in literature until the 1940s. Adenosine is indicated as an adjunct to thallium-201 in myocardial perfusion scintigraphy, though it is rarely used in this indication, having largely been replaced by [dipyridamole]... | Moderate | 1 | [
[
[
1555,
24,
1585
]
],
[
[
1555,
24,
1238
],
[
1238,
40,
1585
]
],
[
[
1555,
64,
1064
],
[
1064,
1,
1585
]
],
[
[
1555,
24,
372
],
[
372,... | [
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Adenosine"
]
],
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentostatin"
],
[
... | Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Pentostatin and Pentostatin (Compound) resembles Adenosine (Compound)
Oxaliplatin may lead to a major life threatening interaction when taken with Cladribine and Cladribine (Compound) resembles Adenosine (Compound)
Oxaliplatin m... |
DB00308 | DB11718 | 347 | 927 | [
"DDInter901",
"DDInter640"
] | Ibutilide | Encorafenib | Ibutilide is a Class III antiarrhythmic agent available in intravenous formulations. It is indicated for the conversion of acute atrial flutter and recent onset atrial fibrillation to normal sinus rhythm (NSR). | Encorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and ... | Major | 2 | [
[
[
347,
25,
927
]
],
[
[
347,
23,
112
],
[
112,
23,
927
]
],
[
[
347,
24,
720
],
[
720,
24,
927
]
],
[
[
347,
25,
1491
],
[
1491,
2... | [
[
[
"Ibutilide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Encorafenib"
]
],
[
[
"Ibutilide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidaz... | Ibutilide may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Encorafenib
Ibutilide may cause a moderate interaction that could exacerbate diseases when taken with Mineral oil and Mine... |
DB00030 | DB00601 | 1,685 | 453 | [
"DDInter934",
"DDInter1073"
] | Insulin human | Linezolid | Human Insulin, also known as Regular Insulin, is a short-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Human insulin is produced by recombinant DNA technology and is identical to endogenously produced insulin. Typically prescribed for the management of diabetes mel... | Linezolid is a synthetic antibiotic which is used for the treatment of infections caused by aerobic Gram-positive bacteria. Its effects are bacteriostatic against both enterococci and staphylococci and bactericidal against most isolates of streptococci. Linezolid exerts its antibacterial activity by inhibiting the init... | Moderate | 1 | [
[
[
1685,
24,
453
]
],
[
[
1685,
24,
850
],
[
850,
63,
453
]
],
[
[
1685,
23,
274
],
[
274,
63,
453
]
],
[
[
1685,
24,
168
],
[
168,
... | [
[
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Linezolid"
]
],
[
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
... | Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin and Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Linezolid
Insulin human may cause a minor interaction that can limit clinical effects when taken with ... |
DB00352 | DB00704 | 482 | 267 | [
"DDInter1814",
"DDInter1263"
] | Tioguanine | Naltrexone | An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia. | Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of naloxone. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence. | Moderate | 1 | [
[
[
482,
24,
267
]
],
[
[
482,
21,
31279
],
[
31279,
60,
267
]
],
[
[
482,
24,
1315
],
[
1315,
24,
267
]
],
[
[
482,
24,
1583
],
[
1583,
... | [
[
[
"Tioguanine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naltrexone"
]
],
[
[
"Tioguanine",
"{u} (Compound) causes {v} (Side Effect)",
"Alcohol abuse"
],
[
"Alcohol abuse",
"{u} (Side Effect)... | Tioguanine (Compound) causes Alcohol abuse (Side Effect) and Alcohol abuse (Side Effect) is caused by Naltrexone (Compound)
Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Chlorzoxazone and Chlorzoxazone may cause a moderate interaction that could exacerbate diseases when take... |
DB01033 | DB11943 | 328 | 255 | [
"DDInter1156",
"DDInter495"
] | Mercaptopurine | Delafloxacin | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | Delafloxacin is a fluoroquinolone antibiotic which has been used in trials studying the treatment and basic science of Gonorrhea, Hepatic Impairment, Bacterial Skin Diseases, Skin Structure Infections, and Community Acquired Pneumonia, among others. It was approved in June 2017 under the trade name Baxdela for use in t... | Minor | 0 | [
[
[
328,
23,
255
]
],
[
[
328,
63,
1001
],
[
1001,
23,
255
]
],
[
[
328,
24,
60
],
[
60,
23,
255
]
],
[
[
328,
74,
482
],
[
482,
23,... | [
[
[
"Mercaptopurine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Delafloxacin"
]
],
[
[
"Mercaptopurine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mechlorethamine"
... | Mercaptopurine may cause a moderate interaction that could exacerbate diseases when taken with Mechlorethamine and Mechlorethamine may cause a minor interaction that can limit clinical effects when taken with Delafloxacin
Mercaptopurine may cause a moderate interaction that could exacerbate diseases when taken with Cap... |
DB10276 | DB15091 | 1,624 | 676 | [
"DDInter1623",
"DDInter1901"
] | Rotavirus vaccine | Upadacitinib | Rotavirus commonly infects children and infants causing severe diarrhea and vomiting leading to potentially fatal dehydration. Two rotavirus vaccines are available for the prevention of rotavirus gastroenteritis, Rotateq and Rotarix. Rotateq is a live vaccine consisting of 5 reassorted human-bovine viral strains. Rotar... | Upadacitinib is an oral Janus kinase (JAK)1-selective inhibitor and a disease-modifying antirheumatic drug (DMARD) used in the treatment of rheumatoid arthritis to slow down disease progression. Rheumatoid arthritis is a chronic autoimmune inflammatory disease affecting the peripheral joints. It is characterized by syn... | Major | 2 | [
[
[
1624,
25,
676
]
],
[
[
1624,
64,
1184
],
[
1184,
25,
676
]
],
[
[
1624,
25,
76
],
[
76,
25,
676
]
],
[
[
1624,
63,
617
],
[
617,
... | [
[
[
"Rotavirus vaccine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
]
],
[
[
"Rotavirus vaccine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Anakinra"
],
[
"Anakinra",
... | Rotavirus vaccine may lead to a major life threatening interaction when taken with Anakinra and Anakinra may lead to a major life threatening interaction when taken with Upadacitinib
Rotavirus vaccine may lead to a major life threatening interaction when taken with Mogamulizumab and Mogamulizumab may lead to a major li... |
DB00087 | DB00242 | 599 | 1,064 | [
"DDInter41",
"DDInter392"
] | Alemtuzumab | Cladribine | Alemtuzumab is a humanized monoclonal antibody specific to lymphocyte antigens. It is a recombinant DNA-derived humanized monoclonal antibody (Campath-1H) that is directed against the 21-28 kD cell surface glycoprotein, CD52. The Campath-1H antibody is an IgG1 kappa with the human variable framework and constant region... | An antineoplastic agent used in the treatment of lymphoproliferative diseases including hairy-cell leukemia. | Major | 2 | [
[
[
599,
25,
1064
]
],
[
[
599,
24,
1426
],
[
1426,
64,
1064
]
],
[
[
599,
24,
1270
],
[
1270,
63,
1064
]
],
[
[
599,
63,
1253
],
[
1253,
... | [
[
[
"Alemtuzumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
]
],
[
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Azacitidine"
],
[
"Azaciti... | Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Azacitidine and Azacitidine may lead to a major life threatening interaction when taken with Cladribine
Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein deri... |
DB00046 | DB02546 | 1,179 | 137 | [
"DDInter940",
"DDInter1947"
] | Insulin lispro | Vorinostat | Insulin lispro is a rapid-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promote... | Vorinostat (rINN) or suberoylanilide hydroxamic acid (SAHA), is a drug currently under investigation for the treatment of cutaneous T cell lymphoma (CTCL), a type of skin cancer, to be used when the disease persists, gets worse, or comes back during or after treatment with other medicines. It is the first in a new clas... | Moderate | 1 | [
[
[
1179,
24,
137
]
],
[
[
1179,
24,
127
],
[
127,
24,
137
]
],
[
[
1179,
24,
1344
],
[
1344,
63,
137
]
],
[
[
1179,
24,
127
],
[
127,
... | [
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vorinostat"
]
],
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Miglitol"
],
... | Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Miglitol and Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Vorinostat
Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin and... |
DB00816 | DB01284 | 1,674 | 1,042 | [
"DDInter1346",
"DDInter1782"
] | Orciprenaline | Tetracosactide | A beta-adrenergic agonist used in the treatment of asthma and bronchospasms. [PubChem] | Tetracosactide (also known as Cosyntropin) is a synthetic peptide that is identical to the 24-amino acid segment (sequence: SYSMEHFRWGKPVGKKRRPVKVYP) at the N-terminal of adrenocorticotropic hormone. ACTH (1-24), a segment similar in all species, contains the biological activity that stimulates production of corticoste... | Minor | 0 | [
[
[
1674,
23,
1042
]
],
[
[
1674,
24,
209
],
[
209,
62,
1042
]
],
[
[
1674,
24,
455
],
[
455,
23,
1042
]
],
[
[
1674,
35,
1148
],
[
1148,
... | [
[
[
"Orciprenaline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tetracosactide"
]
],
[
[
"Orciprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Racepinephrine"
... | Orciprenaline may cause a moderate interaction that could exacerbate diseases when taken with Racepinephrine and Racepinephrine may cause a minor interaction that can limit clinical effects when taken with Tetracosactide
Orciprenaline may cause a moderate interaction that could exacerbate diseases when taken with Salme... |
DB09098 | DB11652 | 98 | 1,155 | [
"DDInter1700",
"DDInter1891"
] | Somatrem | Tucatinib | Despite the ability of almost all contemporary recombinant growth hormones to cause definite and demonstrable increases in growth rate in patients who are administered the drug, the use of these agents continues to be mired in persistent bioethical debate. Such discussion revolves around whether patients' natural dispo... | Tucatinib is a kinase inhibitor drug used with [trastuzumab] and [capecitabine] in the treatment of unresectable or metastatic HER-2 positive breast cancer. It was developed by Seattle Genetics and approved by the FDA on April 17, 2020. Tucatinib is a promising new treatment for patients with metastatic breast cancer w... | Moderate | 1 | [
[
[
98,
24,
1155
]
],
[
[
98,
63,
222
],
[
222,
23,
1155
]
],
[
[
98,
64,
1101
],
[
1101,
23,
1155
]
],
[
[
98,
63,
1424
],
[
1424,
... | [
[
[
"Somatrem",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tucatinib"
]
],
[
[
"Somatrem",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
... | Somatrem may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Tucatinib
Somatrem may lead to a major life threatening interaction when taken with Bexarotene and Bexarotene may cause a min... |
DB01044 | DB11718 | 246 | 927 | [
"DDInter809",
"DDInter640"
] | Gatifloxacin | Encorafenib | Gatifloxacin is an antibiotic agent and a member of the fourth-generation fluoroquinolone family. It works by inhibiting the bacterial enzymes DNA gyrase and topoisomerase IV. It was first introduced by Bristol-Myers Squibb in 1999 under the brand name Tequin® for the treatment of respiratory tract infections. Gatiflox... | Encorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and ... | Major | 2 | [
[
[
246,
25,
927
]
],
[
[
246,
62,
112
],
[
112,
23,
927
]
],
[
[
246,
24,
720
],
[
720,
24,
927
]
],
[
[
246,
62,
372
],
[
372,
24,... | [
[
[
"Gatifloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Encorafenib"
]
],
[
[
"Gatifloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metr... | Gatifloxacin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Encorafenib
Gatifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Mineral oil an... |
DB00327 | DB01181 | 421 | 1,532 | [
"DDInter890",
"DDInter906"
] | Hydromorphone | Ifosfamide | Hydromorphone is a pure opioid, a semi-synthetic hydrogenated ketone derivative of [morphine] that has been available clinically since 1920. Structurally, hydromorphone derived from [morphine] in the modification of the hydroxyl group in the carbon 6 to a carbonyl and the absence of a double bond between the carbon 7 a... | Ifosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppressive agent. | Moderate | 1 | [
[
[
421,
24,
1532
]
],
[
[
421,
6,
6017
],
[
6017,
45,
1532
]
],
[
[
421,
21,
28956
],
[
28956,
60,
1532
]
],
[
[
421,
63,
1648
],
[
1648,... | [
[
[
"Hydromorphone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ifosfamide"
]
],
[
[
"Hydromorphone",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compo... | Hydromorphone (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Ifosfamide (Compound)
Hydromorphone (Compound) causes Palpitations (Side Effect) and Palpitations (Side Effect) is caused by Ifosfamide (Compound)
Hydromorphone may cause a moderate interaction that could exacerbate diseases when taken with Alde... |
DB00390 | DB01390 | 1,252 | 1,117 | [
"DDInter554",
"DDInter1683"
] | Digoxin | Sodium bicarbonate | Digoxin is one of the oldest cardiovascular medications used today. It is a common agent used to manage atrial fibrillation and the symptoms of heart failure. Digoxin is classified as a cardiac glycoside and was initially approved by the FDA in 1954. This drug originates from the foxglove plant, also known as the _Digi... | Sodium bicarbonate is a white, crystalline powder that is commonly used as a pH buffering agent, an electrolyte replenisher, systemic alkalizer and in topical cleansing solutions. | Minor | 0 | [
[
[
1252,
23,
1117
]
],
[
[
1252,
21,
29601
],
[
29601,
60,
1117
]
],
[
[
1252,
24,
1220
],
[
1220,
23,
1117
]
],
[
[
1252,
62,
1018
],
[
... | [
[
[
"Digoxin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sodium bicarbonate"
]
],
[
[
"Digoxin",
"{u} (Compound) causes {v} (Side Effect)",
"Necrosis"
],
[
"Necrosis",
"{u} (Side Effect) is caused... | Digoxin (Compound) causes Necrosis (Side Effect) and Necrosis (Side Effect) is caused by Sodium bicarbonate (Compound)
Digoxin may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may cause a minor interaction that can limit clinical effects when taken with Sod... |
DB00575 | DB00860 | 1,020 | 891 | [
"DDInter412",
"DDInter1513"
] | Clonidine | Prednisolone | Clonidine is an imidazole derivate that acts as an agonist of alpha-2 adrenoceptors. This activity is useful for the treatment of hypertension, severe pain, and ADHD.[L7237,L7240,L7243,L7246] Clonidine was granted FDA approval on 3 September 1974. | Prednisolone is a glucocorticoid similar to [cortisol] used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects. Prednisolone was granted FDA approval on 21 June 1955. | Moderate | 1 | [
[
[
1020,
24,
891
]
],
[
[
1020,
24,
175
],
[
175,
40,
891
]
],
[
[
1020,
24,
167
],
[
167,
1,
891
]
],
[
[
1020,
63,
251
],
[
251,
... | [
[
[
"Clonidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisolone"
]
],
[
[
"Clonidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triamcinolone"
],
[... | Clonidine may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone (Compound) resembles Prednisolone (Compound)
Clonidine may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone (Compound) resembles Predniso... |
DB00414 | DB08907 | 590 | 1,344 | [
"DDInter16",
"DDInter280"
] | Acetohexamide | Canagliflozin | A sulfonylurea hypoglycemic agent that is metabolized in the liver to 1-hydrohexamide. Acetohexamide has been discontinued in the US market. | Canagliflozin, also known as _Invokana_, is a sodium-glucose cotransporter 2 (SGLT2) inhibitor used in the management of type 2 diabetes mellitus along with lifestyle changes including diet and exercise [FDA label]. It was initially approved by the FDA in 2013 for the management of diabetes and later approved in 2018 f... | Moderate | 1 | [
[
[
590,
24,
1344
]
],
[
[
590,
24,
549
],
[
549,
1,
1344
]
],
[
[
590,
62,
1103
],
[
1103,
23,
1344
]
],
[
[
590,
24,
1033
],
[
1033,
... | [
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
]
],
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapagliflozin"
... | Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin and Dapagliflozin (Compound) resembles Canagliflozin (Compound)
Acetohexamide may cause a minor interaction that can limit clinical effects when taken with Amcinonide and Amcinonide may cause a minor interaction ... |
DB00188 | DB13928 | 168 | 1,385 | [
"DDInter222",
"DDInter1660"
] | Bortezomib | Semaglutide | Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest ... | Semaglutide is a glucagon-like peptide 1 (GLP-1) analog used to manage type 2 diabetes along with lifestyle changes, such as dietary restrictions and increased physical activity.[A31421,L8681] Other members of this drug class include [Exenatide] and [Liraglutide]. Semaglutide was developed by Novo Nordisk and approved ... | Moderate | 1 | [
[
[
168,
24,
1385
]
],
[
[
168,
24,
637
],
[
637,
24,
1385
]
],
[
[
168,
23,
1476
],
[
1476,
24,
1385
]
],
[
[
168,
63,
305
],
[
305,
... | [
[
[
"Bortezomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Semaglutide"
]
],
[
[
"Bortezomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Erwinia chrys... | Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Erwinia chrysanthemi and Asparaginase Erwinia chrysanthemi may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide
Bortezomib may cause a minor interaction that can limit clinical ... |
DB00675 | DB00857 | 888 | 1,387 | [
"DDInter1744",
"DDInter1768"
] | Tamoxifen | Terbinafine | Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations.[A1025,L7799,L7802] Tamoxifen is used alone or as an adjuvant in these treatments.[L7799,L7802] Tamoxifen may no longer be the preferred treatment ... | Terbinafine hydrochloride (Lamisil) is a synthetic allylamine antifungal.[L9065,L9068] It is highly lipophilic in nature and tends to accumulate in skin, nails, and fatty tissues. Like other allylamines, terbinafine inhibits ergosterol synthesis by inhibiting the fungal squalene monooxygenase (also called squalene epox... | Major | 2 | [
[
[
888,
25,
1387
]
],
[
[
888,
40,
11247
],
[
11247,
40,
1387
]
],
[
[
888,
6,
8374
],
[
8374,
45,
1387
]
],
[
[
888,
7,
6134
],
[
6134,
... | [
[
[
"Tamoxifen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Terbinafine"
]
],
[
[
"Tamoxifen",
"{u} (Compound) resembles {v} (Compound)",
"Naftifine"
],
[
"Naftifine",
"{u} (Compound) resembles {v} (Compound)",... | Tamoxifen (Compound) resembles Naftifine (Compound) and Naftifine (Compound) resembles Terbinafine (Compound)
Tamoxifen (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Terbinafine (Compound)
Tamoxifen (Compound) upregulates SQLE (Gene) and SQLE (Gene) is bound by Terbinafine (Compound)
Tamoxifen (Compound)... |
DB00398 | DB11799 | 79 | 627 | [
"DDInter1702",
"DDInter205"
] | Sorafenib | Bictegravir | Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular ca... | Bictegravir is a recently approved investigational drug that has been used in trials studying the treatment of HIV-1 and HIV-2 infection. It has been approved for HIV-1 monotherapy combined with 2 other antiretrovirals in a single tablet. | Moderate | 1 | [
[
[
79,
24,
627
]
],
[
[
79,
24,
1362
],
[
1362,
24,
627
]
],
[
[
79,
25,
478
],
[
478,
24,
627
]
],
[
[
79,
63,
600
],
[
600,
24,
... | [
[
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bictegravir"
]
],
[
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
],
[
... | Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Olaparib and Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Bictegravir
Sorafenib may lead to a major life threatening interaction when taken with Nilotinib and Nilotinib may cause a moder... |
DB00069 | DB04845 | 367 | 309 | [
"DDInter946",
"DDInter1001"
] | Interferon alfacon-1 | Ixabepilone | Interferon alfacon-1 is a recombinant non-naturally occurring type-I interferon. The 166-amino acid sequence of Interferon alfacon-1 was derived by scanning the sequences of several natural interferon alpha subtypes and assigning the most frequently observed amino acid in each corresponding position. Four additional am... | Ixabepilone is an epothilone B analog developed by Bristol-Myers Squibb as a cancer drug. It was FDA approved on October 16, 2007, for the treatment of unresponsive aggressive metastatic or locally advanced breast cancer. Ixabepilone is administered through injection, and will be marketed under the trade name Ixempra. ... | Moderate | 1 | [
[
[
367,
24,
309
]
],
[
[
367,
25,
139
],
[
139,
24,
309
]
],
[
[
367,
24,
1434
],
[
1434,
63,
309
]
],
[
[
367,
24,
1487
],
[
1487,
... | [
[
[
"Interferon alfacon-1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixabepilone"
]
],
[
[
"Interferon alfacon-1",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Zidovudine"
],
... | Interferon alfacon-1 may lead to a major life threatening interaction when taken with Zidovudine and Zidovudine may cause a moderate interaction that could exacerbate diseases when taken with Ixabepilone
Interferon alfacon-1 may cause a moderate interaction that could exacerbate diseases when taken with Benznidazole an... |
DB00421 | DB09049 | 443 | 1,135 | [
"DDInter1707",
"DDInter1261"
] | Spironolactone | Naloxegol | Spironolactone is a potassium-sparing diuretic. It binds to mineralocorticoid receptors and functions as aldosterone antagonists. It promotes sodium and water excretion and potassium retention. Spironolactone was originally developed purely for this ability before other pharmacodynamic properties of the drug were disco... | Naloxegol, for "PEGylated naloxol" is a peripherally-selective opioid antagonist developed by AstraZeneca. It was approved by the FDA in September 2014 and is indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non‑cancer pain. The advantage of naloxegol over the opioid antag... | Minor | 0 | [
[
[
443,
23,
1135
]
],
[
[
443,
24,
971
],
[
971,
62,
1135
]
],
[
[
443,
24,
1374
],
[
1374,
23,
1135
]
],
[
[
443,
25,
1456
],
[
1456,
... | [
[
[
"Spironolactone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naloxegol"
]
],
[
[
"Spironolactone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
],
... | Spironolactone may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib and Gilteritinib may cause a minor interaction that can limit clinical effects when taken with Naloxegol
Spironolactone may cause a moderate interaction that could exacerbate diseases when taken with Abiraterone ... |
DB06674 | DB11714 | 908 | 1,316 | [
"DDInter837",
"DDInter610"
] | Golimumab | Durvalumab | Golimumab is a human IgG1қ monoclonal antibody derived from immunizing genetically engineered mice with human TNFα. Golimumab binds and inhibits soluble and transmembrane human TNFα. Increased TNFα is associated with chronic inflammation. Thus golimumab is indicated for use in adults (i) as an adjunct to methotrexate t... | Durvalumab is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody and a novel immune-checkpoint inhibitor for cancer treatment. Produced by recombinant DNA technology in Chinese Hamster Ovary (CHO) cell suspension culture, durvalumab is a programmed death-ligand 1 (PD-L1) blocking antibody that works to promote... | Major | 2 | [
[
[
908,
25,
1316
]
],
[
[
908,
62,
1461
],
[
1461,
23,
1316
]
],
[
[
908,
23,
1114
],
[
1114,
23,
1316
]
],
[
[
908,
64,
167
],
[
167,
... | [
[
[
"Golimumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Durvalumab"
]
],
[
[
"Golimumab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vitamin E"
],
[
"Vitamin E",
... | Golimumab may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Durvalumab
Golimumab may cause a minor interaction that can limit clinical effects when taken with Zinc sulfate and Zinc sulfate m... |
DB00899 | DB09268 | 411 | 1,662 | [
"DDInter1579",
"DDInter1464"
] | Remifentanil | Picosulfuric acid | Remifentanil (marketed by Abbott as Ultiva) is a potent ultra short-acting synthetic opioid given to patients during surgery for pain relief and adjunctive to an anaesthetic. Remifentanil is a specific mu-type-opioid receptor agonist which means it reduces sympathetic nervous system tone, and causes respiratory depress... | Picosulfuric acid is found in laxative products. Sodium picosulfate is a used to treat constipation or induce colon cleansing to prepare the large bowels before colonoscopy or surgery. The combination product containing sodium picosulfate and magnesium citrate was introduced to the Canadian market in 2005 and has been ... | Moderate | 1 | [
[
[
411,
24,
1662
]
],
[
[
411,
63,
73
],
[
73,
24,
1662
]
],
[
[
411,
64,
1494
],
[
1494,
24,
1662
]
],
[
[
411,
1,
1322
],
[
1322,
... | [
[
[
"Remifentanil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Remifentanil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phentermine"
... | Remifentanil may cause a moderate interaction that could exacerbate diseases when taken with Phentermine and Phentermine may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Remifentanil may lead to a major life threatening interaction when taken with Palonosetron and Palono... |
DB01100 | DB12267 | 1,568 | 1,476 | [
"DDInter1470",
"DDInter233"
] | Pimozide | Brigatinib | A diphenylbutylpiperidine that is effective as an antipsychotic agent and as an alternative to haloperidol for the suppression of vocal and motor tics in patients with Tourette syndrome. Although the precise mechanism of action is unknown, blockade of postsynaptic dopamine receptors has been postulated. (From AMA Drug ... | Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the E... | Moderate | 1 | [
[
[
1568,
24,
1476
]
],
[
[
1568,
63,
629
],
[
629,
24,
1476
]
],
[
[
1568,
24,
951
],
[
951,
24,
1476
]
],
[
[
1568,
25,
918
],
[
918,
... | [
[
[
"Pimozide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Pimozide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sirolimus"
],
[
"... | Pimozide may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Pimozide may cause a moderate interaction that could exacerbate diseases when taken with Palbociclib and Palbociclib... |
DB00204 | DB00281 | 228 | 608 | [
"DDInter580",
"DDInter1066"
] | Dofetilide | Lidocaine | Dofetilide is a class III antiarrhythmic agent that is approved by the Food and Drug Administration (FDA) for the maintenance of sinus rhythm in individuals prone to the formation of atrial fibrillation and flutter, and for the chemical cardioversion to sinus rhythm from atrial fibrillation and flutter. | Ever since its discovery and availability for sale and use in the late 1940s, lidocaine has become an exceptionally commonly used medication . In particular, lidocaine's principal mode of action in acting as a local anesthetic that numbs the sensations of tissues means the agent is indicated for facilitating local anes... | Major | 2 | [
[
[
228,
25,
608
]
],
[
[
228,
6,
8374
],
[
8374,
45,
608
]
],
[
[
228,
21,
28722
],
[
28722,
60,
608
]
],
[
[
228,
23,
1101
],
[
1101,
... | [
[
[
"Dofetilide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lidocaine"
]
],
[
[
"Dofetilide",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Lidocain... | Dofetilide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Lidocaine (Compound)
Dofetilide (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Lidocaine (Compound)
Dofetilide may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene may... |
DB11691 | DB11979 | 1,499 | 1,320 | [
"DDInter1258",
"DDInter625"
] | Naldemedine | Elagolix | Naldemedine is an opioid receptor antagonist [FDA Label]. It is a modified form of to which a side chain has been added to increase molecular weight and polar surface area resulting in restricted transport across the blood brain barrier. Naldemedine was approved in 2017 in both the US and Japan for the treatment of Opi... | Elagolix has been used in trials studying the basic science and treatment of Endometriosis, Folliculogenesis, Uterine Fibroids, Heavy Uterine Bleeding, and Heavy Menstrual Bleeding. As of 24 July 2018, however, the U.S. Food and Drug Administration (FDA) approved AbbVie's elagolix under the brand name Orilissa as the f... | Moderate | 1 | [
[
[
1499,
24,
1320
]
],
[
[
1499,
63,
79
],
[
79,
24,
1320
]
],
[
[
1499,
64,
129
],
[
129,
24,
1320
]
],
[
[
1499,
25,
913
],
[
913,
... | [
[
[
"Naldemedine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
]
],
[
[
"Naldemedine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sorafenib"
],
[
... | Naldemedine may cause a moderate interaction that could exacerbate diseases when taken with Sorafenib and Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Elagolix
Naldemedine may lead to a major life threatening interaction when taken with Enzalutamide and Enzalutamide may caus... |
DB00209 | DB00598 | 352 | 1,523 | [
"DDInter1886",
"DDInter1013"
] | Trospium | Labetalol | Trospium is an antispasmodic agent used to treat the symptoms of overactive bladder, a condition that causes the bladder muscles to contract uncontrollably. An overactive bladder leads to an increased urge to urinate, frequent urination, and sometimes, loss of control over urination. Trospium is manufactured by _Indevu... | Labetalol is a racemic mixture of 2 diastereoisomers where dilevalol, the R,R' stereoisomer, makes up 25% of the mixture. Labetalol is formulated as an injection or tablets to treat hypertension.[L7727,L7730] Labetalol was granted FDA approval on 1 August 1984. | Moderate | 1 | [
[
[
352,
24,
1523
]
],
[
[
352,
24,
211
],
[
211,
1,
1523
]
],
[
[
352,
6,
12523
],
[
12523,
45,
1523
]
],
[
[
352,
21,
28827
],
[
28827,
... | [
[
[
"Trospium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Labetalol"
]
],
[
[
"Trospium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolterodine"
],
[
... | Trospium may cause a moderate interaction that could exacerbate diseases when taken with Tolterodine and Tolterodine (Compound) resembles Labetalol (Compound)
Trospium (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Labetalol (Compound)
Trospium (Compound) causes Orthostatic hypotension (Side Effect) and O... |
DB09098 | DB14840 | 98 | 861 | [
"DDInter1700",
"DDInter1601"
] | Somatrem | Ripretinib | Despite the ability of almost all contemporary recombinant growth hormones to cause definite and demonstrable increases in growth rate in patients who are administered the drug, the use of these agents continues to be mired in persistent bioethical debate. Such discussion revolves around whether patients' natural dispo... | Ripretinib is a kinase inhibitor used for the treatment of advanced gastrointestinal stromal tumor (GIST) that has not adequately responded to other kinase inhibitors such as [sunitinib] and [imatinib]. Ripretinib, also known as Qinlock, is manufactured by Deciphera Pharmaceuticals and was initially approved by the FDA... | Moderate | 1 | [
[
[
98,
24,
861
]
],
[
[
98,
24,
351
],
[
351,
24,
861
]
],
[
[
98,
63,
392
],
[
392,
24,
861
]
],
[
[
98,
64,
1101
],
[
1101,
24,
... | [
[
[
"Somatrem",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ripretinib"
]
],
[
[
"Somatrem",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
],
[
... | Somatrem may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Ripretinib
Somatrem may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib and Lapatinib m... |
DB00843 | DB01169 | 479 | 57 | [
"DDInter583",
"DDInter120"
] | Donepezil | Arsenic trioxide | In 2016, the global burden of dementia was estimated to be 43.8 million, demonstrating a significant increase from a global prevalence of 20.2 million in 1990. Donepezil, also known as Aricept, is a piperidine derivative acetylcholinesterase inhibitor used in the management of the dementia of Alzheimer's Disease, and i... | Arsenic trioxide is a chemotherapeutic agent of idiopathic function used to treat leukemia that is unresponsive to first line agents. It is suspected that arsenic trisulfide induces cancer cells to undergo apoptosis. In general, arsenic is known to be a naturally toxic substance capable of eliciting a variety of danger... | Moderate | 1 | [
[
[
479,
24,
57
]
],
[
[
479,
6,
8374
],
[
8374,
45,
57
]
],
[
[
479,
24,
112
],
[
112,
23,
57
]
],
[
[
479,
24,
144
],
[
144,
63,
... | [
[
[
"Donepezil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Arsenic trioxide"
]
],
[
[
"Donepezil",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compoun... | Donepezil (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Arsenic trioxide (Compound)
Donepezil may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Arsenic trioxide
Done... |
DB00557 | DB00761 | 252 | 1,621 | [
"DDInter895",
"DDInter1497"
] | Hydroxyzine | Potassium chloride | Hydroxyzine is a first-generation histamine H<sub>1</sub>-receptor antagonist of the dephenylmethane and piperazine classes that exhibits sedative, anxiolytic, and antiemetic properties.[A1257,A187589] It was first developed in 1955, and has since remained a relatively common treatment for allergic conditions such as p... | A white crystal or crystalline powder used as an electrolyte replenisher, in the treatment of hypokalemia, in buffer solutions, and in fertilizers and explosives. The FDA withdrew its approval for the use of all solid oral dosage form drug products containing potassium chloride that supply 100 mg or more of potassium p... | Major | 2 | [
[
[
252,
25,
1621
]
],
[
[
252,
21,
28766
],
[
28766,
60,
1621
]
],
[
[
252,
63,
13
],
[
13,
25,
1621
]
],
[
[
252,
24,
100
],
[
100,
... | [
[
[
"Hydroxyzine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Potassium chloride"
]
],
[
[
"Hydroxyzine",
"{u} (Compound) causes {v} (Side Effect)",
"Hypotension"
],
[
"Hypotension",
"{u} (Side Effect) is cause... | Hydroxyzine (Compound) causes Hypotension (Side Effect) and Hypotension (Side Effect) is caused by Potassium chloride (Compound)
Hydroxyzine may cause a moderate interaction that could exacerbate diseases when taken with Cyproheptadine and Cyproheptadine may lead to a major life threatening interaction when taken with ... |
DB00214 | DB11921 | 1,028 | 1,019 | [
"DDInter1836",
"DDInter492"
] | Torasemide | Deflazacort | Torasemide is a high-ceiling loop diuretic. Structurally, it is a pyridine-sulfonylurea used as an antihypertensive agent. Torasemide was first approved for clinical use by the FDA in 1993. | Deflazacort, also known as Emflaza, is a corticosteroid prodrug used as an agent to manage Duchenne Muscular Dystrophy (DMD). It is marketed by Marathon Pharmaceuticals and was approved in February 2017 by the FDA.[L6694,FDA label] Duchenne Muscular Dystrophy is an inherited disorder resulting from mutations of the dys... | Moderate | 1 | [
[
[
1028,
24,
1019
]
],
[
[
1028,
24,
959
],
[
959,
24,
1019
]
],
[
[
1028,
24,
1619
],
[
1619,
63,
1019
]
],
[
[
1028,
63,
176
],
[
176,
... | [
[
[
"Torasemide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deflazacort"
]
],
[
[
"Torasemide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
[
... | Torasemide may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort
Torasemide may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucapari... |
DB00361 | DB01101 | 134 | 60 | [
"DDInter1939",
"DDInter285"
] | Vinorelbine | Capecitabine | Vinorelbine is an anti-mitotic chemotherapy drug that is used in the treatment of several types of malignancies, including breast cancer and non-small cell lung cancer (NSCLC). It was initially approved in the USA in 1990's for the treatment of NSCLC. It is a third-generation vinca alkaloid. The introduction of third-g... | Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue. | Moderate | 1 | [
[
[
134,
24,
60
]
],
[
[
134,
5,
11579
],
[
11579,
44,
60
]
],
[
[
134,
18,
8569
],
[
8569,
45,
60
]
],
[
[
134,
21,
28701
],
[
28701,
... | [
[
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Capecitabine"
]
],
[
[
"Vinorelbine",
"{u} (Compound) treats {v} (Disease)",
"breast cancer"
],
[
"breast cancer",
"{u} (Disease) is ... | Vinorelbine (Compound) treats breast cancer (Disease) and breast cancer (Disease) is treated by Capecitabine (Compound)
Vinorelbine (Compound) downregulates TYMS (Gene) and TYMS (Gene) is bound by Capecitabine (Compound)
Vinorelbine (Compound) causes Discomfort (Side Effect) and Discomfort (Side Effect) is caused by Ca... |
DB00687 | DB06643 | 870 | 1,136 | [
"DDInter747",
"DDInter500"
] | Fludrocortisone | Denosumab | Fludrocortisone is a synthetic mineralocorticoid used in conjunction with [hydrocortisone] to replace missing endogenous corticosteroids in patients with adrenal insufficiency.[A187169,A187187] It is functionally similar to [aldosterone], the body's primary endogenous mineralocorticoid, and is structurally analogous to... | Denosumab is a novel, fully human IgG2 monoclonal antibody specific to receptor activator of nuclear factor kappa-B ligand (RANKL), suppresses bone resorption via inhibiting RANK-mediated activation of osteoclasts. It is the first and currently the only RANKL inhibitor approved to prevent osteoclast-mediated bone loss.... | Moderate | 1 | [
[
[
870,
24,
1136
]
],
[
[
870,
24,
1213
],
[
1213,
24,
1136
]
],
[
[
870,
63,
1419
],
[
1419,
24,
1136
]
],
[
[
870,
1,
251
],
[
251,
... | [
[
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Denosumab"
]
],
[
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dasatinib"
],
... | Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Denosumab
Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and I... |
DB06688 | DB14004 | 1,430 | 398 | [
"DDInter1677",
"DDInter1806"
] | Sipuleucel-T | Tildrakizumab | Sipuleucel-T is a personalized, autologous, cellular immunotherapy. Sipuleucel-T is a therapeutic cancer vaccine for prostate cancer. Sipuleucel-T selectively targets the prostate-specific antigen (PSA) known as prostatic acid phosphatase (PAP) that is expressed in around 95% of prostate cancers. It must be prepared sp... | Tildrakizumab is a high-affinity, humanized, IgG1 κ antibody targeting interleukin 23 p19 that shows promise in the evolution of treatment strategy in chronic plaque psoriasis . The Food and Drug Administration (FDA) approved ILUMYA (tildrakizumab-asmn) for the treatment of adults with moderate-to-severe plaque psorias... | Moderate | 1 | [
[
[
1430,
24,
398
]
],
[
[
1430,
63,
58
],
[
58,
24,
398
]
],
[
[
1430,
24,
270
],
[
270,
24,
398
]
],
[
[
1430,
24,
287
],
[
287,
6... | [
[
[
"Sipuleucel-T",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tildrakizumab"
]
],
[
[
"Sipuleucel-T",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alefacept"
],
... | Sipuleucel-T may cause a moderate interaction that could exacerbate diseases when taken with Alefacept and Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Tildrakizumab
Sipuleucel-T may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab and ... |
DB00295 | DB00691 | 475 | 1,058 | [
"DDInter1244",
"DDInter1237"
] | Morphine | Moexipril | Morphine, the main alkaloid of opium, was first obtained from poppy seeds in 1805. It is a potent analgesic, though its use is limited due to tolerance, withdrawal, and the risk of abuse. Morphine is still routinely used today, though there are a number of semi-synthetic opioids of varying strength such as [codeine], [... | Moexipril is a non-sulfhydryl containing precursor of the active angiotensin-converting enzyme (ACE) inhibitor moexiprilat. It is used to treat high blood pressure (hypertension). It works by relaxing blood vessels, causing them to widen. Lowering high blood pressure helps prevent strokes, heart attacks and kidney prob... | Moderate | 1 | [
[
[
475,
24,
1058
]
],
[
[
475,
24,
1638
],
[
1638,
1,
1058
]
],
[
[
475,
24,
954
],
[
954,
40,
1058
]
],
[
[
475,
24,
999
],
[
999,
... | [
[
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Moexipril"
]
],
[
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trandolapril"
],
[
... | Morphine may cause a moderate interaction that could exacerbate diseases when taken with Trandolapril and Trandolapril (Compound) resembles Moexipril (Compound)
Morphine may cause a moderate interaction that could exacerbate diseases when taken with Quinapril and Quinapril (Compound) resembles Moexipril (Compound)
Morp... |
DB00594 | DB01017 | 863 | 1,669 | [
"DDInter68",
"DDInter1224"
] | Amiloride | Minocycline | A pyrazine compound inhibiting sodium reabsorption through sodium channels in renal epithelial cells. This inhibition creates a negative potential in the luminal membranes of principal cells, located in the distal convoluted tubule and collecting duct. Negative potential reduces secretion of potassium and hydrogen ions... | Minocycline was first described in the literacture in 1966. It is a second generation tetracycline antibiotic that is active against gram-negative and gram-positive bacteria. Like other semisynthetic tetracyclines, minocycline has modifications to carbons 7-9 on the D ring to generate higher efficacy than previous tetr... | Minor | 0 | [
[
[
863,
23,
1669
]
],
[
[
863,
23,
1572
],
[
1572,
1,
1669
]
],
[
[
863,
62,
964
],
[
964,
1,
1669
]
],
[
[
863,
23,
1545
],
[
1545,
... | [
[
[
"Amiloride",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Minocycline"
]
],
[
[
"Amiloride",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Demeclocycline"
],
[
... | Amiloride may cause a minor interaction that can limit clinical effects when taken with Demeclocycline and Demeclocycline (Compound) resembles Minocycline (Compound)
Amiloride may cause a minor interaction that can limit clinical effects when taken with Doxycycline and Doxycycline (Compound) resembles Minocycline (Comp... |
DB00572 | DB01619 | 85 | 830 | [
"DDInter136",
"DDInter1441"
] | Atropine | Phenindamine | Atropine is an alkaloid originally synthesized from Atropa belladonna. It is a racemic mixture of d-and l-hyoscyamine, of which only l-hyoscyamine is pharmacologically active.[A251670,L42835] Atropine is generally available as a sulfate salt and can be administered by intravenous, subcutaneous, intramuscular, intraosse... | Phenindamine is an antihistamine. Phenindamine blocks the effects of the naturally occurring chemical histamine in your body. Antihistamines such as phenindamine appear to compete with histamine for histamine H1- receptor sites on effector cells. The antihistamines antagonize those pharmacological effects of histamine ... | Moderate | 1 | [
[
[
85,
24,
830
]
],
[
[
85,
24,
537
],
[
537,
40,
830
]
],
[
[
85,
63,
357
],
[
357,
24,
830
]
],
[
[
85,
24,
104
],
[
104,
1,
... | [
[
[
"Atropine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenindamine"
]
],
[
[
"Atropine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclizine"
],
[
... | Atropine may cause a moderate interaction that could exacerbate diseases when taken with Cyclizine and Cyclizine (Compound) resembles Phenindamine (Compound)
Atropine may cause a moderate interaction that could exacerbate diseases when taken with Benzatropine and Benz
Atropine may cause a moderate interaction that coul... |
DB01041 | DB06372 | 770 | 259 | [
"DDInter1789",
"DDInter1594"
] | Thalidomide | Rilonacept | A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating ... | Rilonacept is a dimeric fusion protein consisting of portions of IL-1R and the IL-1R accessory protein linked to the Fc portion of immunoglobulin G1. Rilonacept functions as an interleukin 1 inhibitor and is used in the treatment of CAPS, also known as cryopyrin-associated periodic syndromes, including familial cold au... | Moderate | 1 | [
[
[
770,
24,
259
]
],
[
[
770,
64,
0
],
[
0,
24,
259
]
],
[
[
770,
24,
1619
],
[
1619,
63,
259
]
],
[
[
770,
24,
1565
],
[
1565,
24,... | [
[
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilonacept"
]
],
[
[
"Thalidomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dactinomycin"
],
[
"Dactin... | Thalidomide may lead to a major life threatening interaction when taken with Dactinomycin and Dactinomycin may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept
Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may ca... |
DB00884 | DB14520 | 1,008 | 1,229 | [
"DDInter1604",
"DDInter1785"
] | Risedronic acid | Tetraferric tricitrate decahydrate | Risedronic acid is a third generation bisphosphonate that is used for the treatment of some forms of osteoperosis and Paget's disease[FDA Label][A959,A203111]. It functions by preventing resorption of bone[FDA Label]. | Tetraferric tricitrate decahydrate is an iron containing phosphate binder used to treat hyperphosphatemia and iron deficiency anemia in adults with chronic kidney disease. Tetraferric tricitrate decahydrate was granted FDA approval on 5 September 2014. | Moderate | 1 | [
[
[
1008,
24,
1229
]
],
[
[
1008,
40,
1485
],
[
1485,
24,
1229
]
],
[
[
1008,
40,
1485
],
[
1485,
1,
1199
],
[
1199,
24,
1229
]
],
[
[
100... | [
[
[
"Risedronic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetraferric tricitrate decahydrate"
]
],
[
[
"Risedronic acid",
"{u} (Compound) resembles {v} (Compound)",
"Alendronic acid"
],
[
"Alen... | Risedronic acid (Compound) resembles Alendronic acid (Compound) and Alendronic acid may cause a moderate interaction that could exacerbate diseases when taken with Tetraferric tricitrate decahydrate
Risedronic acid (Compound) resembles Alendronic acid (Compound) and Alendronic acid (Compound) resembles Ibandronate (Com... |
DB00501 | DB04835 | 752 | 1,655 | [
"DDInter380",
"DDInter1125"
] | Cimetidine | Maraviroc | A histamine congener, it competitively inhibits histamine binding to histamine H2 receptors. Cimetidine has a range of pharmacological actions. It inhibits gastric acid secretion, as well as pepsin and gastrins output. It also blocks the activity of cytochrome P-450 which might explain proposals for use in neoadjuvant ... | Maraviroc (brand-named Selzentry, or Celsentri outside the U.S.) is a chemokine receptor antagonist drug developed by the drug company Pfizer that is designed to act against HIV by interfering with the interaction between HIV and CCR5. It was originally labelled as UK-427857 during development but was assigned the Mara... | Moderate | 1 | [
[
[
752,
24,
1655
]
],
[
[
752,
6,
8374
],
[
8374,
45,
1655
]
],
[
[
752,
21,
28921
],
[
28921,
60,
1655
]
],
[
[
752,
24,
1419
],
[
1419,... | [
[
[
"Cimetidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Maraviroc"
]
],
[
[
"Cimetidine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Cimetidine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Maraviroc (Compound)
Cimetidine (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Maraviroc (Compound)
Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib... |
DB00092 | DB00444 | 58 | 63 | [
"DDInter40",
"DDInter1765"
] | Alefacept | Teniposide | Immunosuppressive dimeric fusion protein that consists of the extracellular CD2-binding portion of the human leukocyte function antigen-3 (LFA-3) linked to the Fc (hinge, CH2 and CH3 domains) portion of human IgG1. Produced by CHO cells, mW is 91.4 kD. | Teniposide is a semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Teniposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent cells ... | Moderate | 1 | [
[
[
58,
24,
63
]
],
[
[
58,
24,
147
],
[
147,
62,
63
]
],
[
[
58,
24,
738
],
[
738,
63,
63
]
],
[
[
58,
23,
1461
],
[
1461,
24,
... | [
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Teniposide"
]
],
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vinblastine"
],
[
... | Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Vinblastine and Vinblastine may cause a minor interaction that can limit clinical effects when taken with Teniposide
Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Niraparib and Niraparib... |
DB00619 | DB01611 | 1,419 | 1,487 | [
"DDInter909",
"DDInter893"
] | Imatinib | Hydroxychloroquine | Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated wi... | Hydroxychloroquine is a racemic mixture consisting of an R and S enantiomer. Hydroxychloroquine is an aminoquinoline like [chloroquine]. It is a commonly prescribed medication in the treatment of uncomplicated malaria, rheumatoid arthritis, chronic discoid lupus erythematosus, and systemic lupus erythematosus. Hydroxyc... | Moderate | 1 | [
[
[
1419,
24,
1487
]
],
[
[
1419,
24,
1520
],
[
1520,
25,
1487
]
],
[
[
1419,
6,
12523
],
[
12523,
45,
1487
]
],
[
[
1419,
21,
28658
],
[
... | [
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxychloroquine"
]
],
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Primaquine"
],
... | Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Primaquine and Primaquine may lead to a major life threatening interaction when taken with Hydroxychloroquine
Imatinib (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Hydroxychloroquine (Compound)
Imatinib (Compound) c... |
DB00783 | DB12500 | 1,438 | 283 | [
"DDInter679",
"DDInter714"
] | Estradiol | Fedratinib | Estradiol is a naturally occurring hormone circulating endogenously in females. It is commercially available in several hormone therapy products for managing conditions associated with reduced estrogen, such as vulvovaginal atrophy and hot flashes. Some available forms of estradiol include oral tablets, injections, vag... | Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis.[A183176,L8090] It is an anilinopyrimidine derivative. Fedratinib was granted FDA approval on August 16, 2019. | Moderate | 1 | [
[
[
1438,
24,
283
]
],
[
[
1438,
63,
1419
],
[
1419,
24,
283
]
],
[
[
1438,
24,
761
],
[
761,
24,
283
]
],
[
[
1438,
1,
559
],
[
559,
... | [
[
[
"Estradiol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Estradiol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Imatinib"
],
[
... | Estradiol may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib
Estradiol may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin and Saxagliptin... |
DB01024 | DB01610 | 1,096 | 248 | [
"DDInter1252",
"DDInter1912"
] | Mycophenolic acid | Valganciclovir | Mycophenolic acid is a potent immunosuppressant agent that inhibits _de novo_ purine biosynthesis. It was derived from _Penicillium stoloniferum_, and has also shown antibacterial, antifungal and antiviral properties.. Mycophenolic acid is used in immunosuppressive regimens as part of a triple therapy that includes a c... | Valganciclovir hydrochloride (Valcyte, manufactured by Roche) is an antiviral medication used to treat cytomegalovirus infections. As the L-valyl ester of ganciclovir, it is actually a prodrug for ganciclovir. After oral administration, it is rapidly converted to ganciclovir by intestinal and hepatic esterases. | Moderate | 1 | [
[
[
1096,
24,
248
]
],
[
[
1096,
62,
387
],
[
387,
1,
248
]
],
[
[
1096,
63,
563
],
[
563,
1,
248
]
],
[
[
1096,
21,
29209
],
[
29209,
... | [
[
[
"Mycophenolic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valganciclovir"
]
],
[
[
"Mycophenolic acid",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Acyclovir"
... | Mycophenolic acid may cause a minor interaction that can limit clinical effects when taken with Acyclovir and Acyclovir (Compound) resembles Valganciclovir (Compound)
Mycophenolic acid may cause a moderate interaction that could exacerbate diseases when taken with Ganciclovir and Ganciclovir (Compound) resembles Valgan... |
DB09020 | DB11853 | 28 | 230 | [
"DDInter212",
"DDInter1577"
] | Bisacodyl | Relugolix | Bisacodyl, a diphenylmethane derivative, is a commonly used over the counter stimulant laxative for occasional constipation.[A233300,L13362] Both bisacodyl and [picosulfate] are metabolized to the same active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM).[A233290,A233300,A207700] Bisacodyl was patented on 2... | Relugolix is a gonadotropin-releasing hormone (GnRH) receptor antagonist used in the treatment of several hormone-responsive conditions. It was first approved in Japan in 2019, under the brand name Relumina, for the symptomatic treatment of uterine fibroids, and more recently by the United States' FDA in 2020, under th... | Moderate | 1 | [
[
[
28,
24,
230
]
],
[
[
28,
63,
129
],
[
129,
23,
230
]
],
[
[
28,
63,
1213
],
[
1213,
24,
230
]
],
[
[
28,
24,
286
],
[
286,
24,
... | [
[
[
"Bisacodyl",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Relugolix"
]
],
[
[
"Bisacodyl",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
],
[
... | Bisacodyl may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may cause a minor interaction that can limit clinical effects when taken with Relugolix
Bisacodyl may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib and Dasatini... |
DB00697 | DB11718 | 876 | 927 | [
"DDInter1821",
"DDInter640"
] | Tizanidine | Encorafenib | Tizanidine is a fast-acting drug used for the management of muscle spasm, which may result from the effects of multiple sclerosis, stroke, an acquired brain injury, or a spinal cord injury. It may also be caused by musculoskeletal injury. Regardless of the cause, muscle spasticity can be an extremely painful and debili... | Encorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and ... | Moderate | 1 | [
[
[
876,
24,
927
]
],
[
[
876,
23,
112
],
[
112,
23,
927
]
],
[
[
876,
24,
659
],
[
659,
24,
927
]
],
[
[
876,
63,
372
],
[
372,
24,... | [
[
[
"Tizanidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
]
],
[
[
"Tizanidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Tizanidine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Encorafenib
Tizanidine may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol and Vil... |
DB01209 | DB11817 | 1,359 | 1,259 | [
"DDInter531",
"DDInter165"
] | Dezocine | Baricitinib | Dezocine is a partial opiate drug and is used for pain management. Dezocine is a very effective alternative to fentanyl when administered during outpatient laparoscopy, although is associated with an increased incidence of postoperative nausea. | Baricitinib is a Janus kinase (JAK) inhibitor. JAKs are tyrosine protein kinases that play an important role in pro-inflammatory signaling pathways. Overactive JAKs have been implicated in autoimmune disorders, such as rheumatoid arthritis. By inhibiting the actions of JAK1 and JAK2, baricitinib attenuates JAK-mediated... | Moderate | 1 | [
[
[
1359,
24,
1259
]
],
[
[
1359,
40,
234
],
[
234,
24,
1259
]
],
[
[
1359,
25,
407
],
[
407,
24,
1259
]
],
[
[
1359,
64,
475
],
[
475,
... | [
[
[
"Dezocine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Baricitinib"
]
],
[
[
"Dezocine",
"{u} (Compound) resembles {v} (Compound)",
"Pentazocine"
],
[
"Pentazocine",
"{u} may cause a moderate... | Dezocine (Compound) resembles Pentazocine (Compound) and Pentazocine may cause a moderate interaction that could exacerbate diseases when taken with Baricitinib
Dezocine may lead to a major life threatening interaction when taken with Opium and Opium may cause a moderate interaction that could exacerbate diseases when ... |
DB00357 | DB00367 | 1,051 | 566 | [
"DDInter71",
"DDInter1061"
] | Aminoglutethimide | Levonorgestrel | An aromatase inhibitor that produces a state of "medical" adrenalectomy by blocking the production of adrenal steroids. It also blocks the conversion of androgens to estrogens. Aminoglutethimide has been used in the treatment of advanced breast and prostate cancer. It was formerly used for its weak anticonvulsant prope... | Levonorgestrel (LNG) is a synthetic progestogen similar to [Progesterone] used in contraception and hormone therapy.[A181988,T659] Also known as Plan B, it is used as a single agent in emergency contraception, and as a hormonal contraceptive released from an intrauterine device, commonly referred to as an IUD. Some of ... | Moderate | 1 | [
[
[
1051,
24,
566
]
],
[
[
1051,
63,
1336
],
[
1336,
40,
566
]
],
[
[
1051,
24,
1197
],
[
1197,
1,
566
]
],
[
[
1051,
6,
8374
],
[
8374,
... | [
[
[
"Aminoglutethimide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levonorgestrel"
]
],
[
[
"Aminoglutethimide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etonogest... | Aminoglutethimide may cause a moderate interaction that could exacerbate diseases when taken with Etonogestrel and Etonogestrel (Compound) resembles Levonorgestrel (Compound)
Aminoglutethimide may cause a moderate interaction that could exacerbate diseases when taken with Norethisterone and Norethisterone (Compound) re... |
DB00631 | DB09074 | 372 | 1,362 | [
"DDInter405",
"DDInter1327"
] | Clofarabine | Olaparib | Clofarabine is a purine nucleoside antimetabolite that is being studied in the treatment of cancer. It is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand. Clofarabine is used in paediatrics to treat a type of leukaemia called relapsed or refractory acute lymphoblastic leukaem... | Olaparib is a selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP1 and PARP2.[L41100, L40908, L43792] PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in cancer cells with BRCA mutations and inducing cell death. Ol... | Moderate | 1 | [
[
[
372,
24,
1362
]
],
[
[
372,
24,
725
],
[
725,
63,
1362
]
],
[
[
372,
24,
896
],
[
896,
24,
1362
]
],
[
[
372,
63,
139
],
[
139,
... | [
[
[
"Clofarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
]
],
[
[
"Clofarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Satralizumab"
],
[
... | Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Satralizumab and Satralizumab may cause a moderate interaction that could exacerbate diseases when taken with Olaparib
Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Etoposide and Eto... |
DB00594 | DB11130 | 863 | 407 | [
"DDInter68",
"DDInter1344"
] | Amiloride | Opium | A pyrazine compound inhibiting sodium reabsorption through sodium channels in renal epithelial cells. This inhibition creates a negative potential in the luminal membranes of principal cells, located in the distal convoluted tubule and collecting duct. Negative potential reduces secretion of potassium and hydrogen ions... | Opium is the first substance of the diverse group of the opiates. It has been known for a long time, and the first evidence of a poppy culture dates from 5 thousand years by the Sumerians. During the years, opium was used as a sedative and hypnotic, but it was determined to be addictive. Opium is extracted from _Papave... | Moderate | 1 | [
[
[
863,
24,
407
]
],
[
[
863,
24,
104
],
[
104,
24,
407
]
],
[
[
863,
63,
1648
],
[
1648,
24,
407
]
],
[
[
863,
62,
752
],
[
752,
2... | [
[
[
"Amiloride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
]
],
[
[
"Amiloride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
],
[
"... | Amiloride may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Opium
Amiloride may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleu... |
DB00443 | DB13139 | 251 | 1,032 | [
"DDInter195",
"DDInter1063"
] | Betamethasone | Levosalbutamol | Betamethasone is a long-acting corticosteroid with immunosuppressive and antiinflammatory properties. It can be used topically to manage inflammatory skin conditions such as eczema, and parenterally to manage several disease states including autoimmune disorders. Betamethasone has potent glucocorticoid activity and neg... | Levosalbutamol, or levalbuterol, is a short-acting β2 adrenergic receptor agonist used in the treatment of asthma and chronic obstructive pulmonary disease (COPD). [Salbutamol] has been marketed as a racemic mixture, although beta2-agonist activity resides almost exclusively in the (R)-enantiomer. The enantioselective ... | Minor | 0 | [
[
[
251,
23,
1032
]
],
[
[
251,
40,
218
],
[
218,
23,
1032
]
],
[
[
251,
1,
1573
],
[
1573,
23,
1032
]
],
[
[
251,
23,
659
],
[
659,
... | [
[
[
"Betamethasone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Levosalbutamol"
]
],
[
[
"Betamethasone",
"{u} (Compound) resembles {v} (Compound)",
"Beclomethasone dipropionate"
],
[
"Beclomethasone dip... | Betamethasone (Compound) resembles Beclomethasone dipropionate (Compound) and Beclomethasone dipropionate may cause a minor interaction that can limit clinical effects when taken with Levosalbutamol
Betamethasone (Compound) resembles Prednisone (Compound) and Prednisone may cause a minor interaction that can limit clin... |
DB00495 | DB01041 | 139 | 770 | [
"DDInter1961",
"DDInter1789"
] | Zidovudine | Thalidomide | A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain... | A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating ... | Moderate | 1 | [
[
[
139,
24,
770
]
],
[
[
139,
63,
1668
],
[
1668,
1,
770
]
],
[
[
139,
6,
10215
],
[
10215,
45,
770
]
],
[
[
139,
21,
28789
],
[
28789,
... | [
[
[
"Zidovudine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
]
],
[
[
"Zidovudine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lenalidomide"
],
[... | Zidovudine may cause a moderate interaction that could exacerbate diseases when taken with Lenalidomide and Lenalidomide (Compound) resembles Thalidomide (Compound)
Zidovudine (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Thalidomide (Compound)
Zidovudine (Compound) causes Loss of consciousness (Side E... |
DB00361 | DB11834 | 134 | 1,303 | [
"DDInter1939",
"DDInter849"
] | Vinorelbine | Guselkumab | Vinorelbine is an anti-mitotic chemotherapy drug that is used in the treatment of several types of malignancies, including breast cancer and non-small cell lung cancer (NSCLC). It was initially approved in the USA in 1990's for the treatment of NSCLC. It is a third-generation vinca alkaloid. The introduction of third-g... | Guselkumab is a human immunoglobulin G1 lambda (IgG1λ) monoclonal antibody that selectively blocks interleukin-23. IL-23 is an inflammatory cytokine that activates the CD4+ T-helper (Th17) cell pathway to mediate the inflammatory cascade that induces psoriatic plaque formation . In clinical trials, guselkumab demonstra... | Moderate | 1 | [
[
[
134,
24,
1303
]
],
[
[
134,
63,
1461
],
[
1461,
23,
1303
]
],
[
[
134,
24,
949
],
[
949,
24,
1303
]
],
[
[
134,
63,
58
],
[
58,
... | [
[
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Guselkumab"
]
],
[
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
... | Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Guselkumab
Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Clostridium tetani toxo... |
DB01072 | DB04868 | 915 | 478 | [
"DDInter129",
"DDInter1293"
] | Atazanavir | Nilotinib | Atazanavir (formerly known as BMS-232632) is an antiretroviral drug of the protease inhibitor (PI) class. Like other antiretrovirals, it is used to treat infection of human immunodeficiency virus (HIV). Atazanavir is distinguished from other PIs in that it can be given once daily (rather than requiring multiple doses p... | Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to ... | Major | 2 | [
[
[
915,
25,
478
]
],
[
[
915,
25,
1468
],
[
1468,
63,
478
]
],
[
[
915,
6,
6017
],
[
6017,
45,
478
]
],
[
[
915,
21,
31778
],
[
31778,
... | [
[
[
"Atazanavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nilotinib"
]
],
[
[
"Atazanavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ponatinib"
],
[
"Ponatinib",
"{u} may ... | Atazanavir may lead to a major life threatening interaction when taken with Ponatinib and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib
Atazanavir (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Nilotinib (Compound)
Atazanavir (Compound) causes Bundle b... |
DB00006 | DB00215 | 942 | 1,230 | [
"DDInter217",
"DDInter388"
] | Bivalirudin | Citalopram | Bivalirudin is a synthetic 20 residue peptide (thrombin inhibitor) which reversibly inhibits thrombin. Once bound to the active site, thrombin cannot activate fibrinogen into fibrin, the crucial step in the formation of thrombus. It is administered intravenously. Because it can cause blood stagnation, it is important t... | Citalopram is an antidepressant belonging to the class of selective _serotonin-reuptake inhibitors_ (SSRIs) widely used to treat the symptoms of depression. It is a racemic bicyclic phthalate derivate and is the only compound with a tertiary amine and 2 nitrogen-containing metabolites among all SSRIs.[A261316,A14720] C... | Moderate | 1 | [
[
[
942,
24,
1230
]
],
[
[
942,
24,
318
],
[
318,
40,
1230
]
],
[
[
942,
25,
500
],
[
500,
63,
1230
]
],
[
[
942,
24,
885
],
[
885,
... | [
[
[
"Bivalirudin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Citalopram"
]
],
[
[
"Bivalirudin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Escitalopram"
],
... | Bivalirudin may cause a moderate interaction that could exacerbate diseases when taken with Escitalopram and Escitalopram (Compound) resembles Citalopram (Compound)
Bivalirudin may lead to a major life threatening interaction when taken with Enoxaparin and Enoxaparin may cause a moderate interaction that could exacerba... |
DB11757 | DB12364 | 960 | 1,421 | [
"DDInter994",
"DDInter200"
] | Istradefylline | Betrixaban | Istradefylline, or KW6002, was developed by Kyowa Hakko Kirin in Japan for the treatment of Parkinson's disease as an adjunct to standard therapy. Unlike standard dopaminergic therapies for Parkinson's, Istradefylline targets adenosine A<sub>2A</sub> receptors in the basal ganglia. This region of the brain is highly in... | Betrixaban is a non-vitamin K oral anticoagulant whose action is driven by the competitive and reversible inhibition of the factor Xa . It was selected among all lead compounds due to its low hERG channel affinity while sustaining its factor Xa inhibition capacity . Betrixaban, now developed by Portola Pharmaceuticals ... | Moderate | 1 | [
[
[
960,
24,
1421
]
],
[
[
960,
24,
1017
],
[
1017,
24,
1421
]
],
[
[
960,
64,
760
],
[
760,
24,
1421
]
],
[
[
960,
63,
1593
],
[
1593,
... | [
[
[
"Istradefylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Betrixaban"
]
],
[
[
"Istradefylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
],
... | Istradefylline may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Betrixaban
Istradefylline may lead to a major life threatening interaction when taken with Cobicistat and Cobicistat ma... |
DB00586 | DB00775 | 1,512 | 1,226 | [
"DDInter537",
"DDInter1818"
] | Diclofenac | Tirofiban | Diclofenac is a phenylacetic acid derivative and non-steroidal anti-inflammatory drug (NSAID).[label] NSAIDs inhibit cyclooxygenase (COX)-1 and-2 which are the enzyme responsible for producing prostaglandins (PGs). PGs contribute to inflammation and pain signalling. Diclofenac, like other NSAIDs, is often used as first... | Tirofiban prevents the blood from clotting during episodes of chest pain or a heart attack, or while the patient is undergoing a procedure to treat a blocked coronary artery. It is a non-peptide reversible antagonist of the platelet glycoprotein (GP) IIb/IIIa receptor, and inhibits platelet aggregation. | Moderate | 1 | [
[
[
1512,
24,
1226
]
],
[
[
1512,
21,
28681
],
[
28681,
60,
1226
]
],
[
[
1512,
23,
297
],
[
297,
62,
1226
]
],
[
[
1512,
24,
714
],
[
714... | [
[
[
"Diclofenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tirofiban"
]
],
[
[
"Diclofenac",
"{u} (Compound) causes {v} (Side Effect)",
"Hypersensitivity"
],
[
"Hypersensitivity",
"{u} (Side Ef... | Diclofenac (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Tirofiban (Compound)
Diclofenac may cause a minor interaction that can limit clinical effects when taken with Clove and Clove may cause a minor interaction that can limit clinical effects when taken with Tirofiba... |
DB01168 | DB01610 | 1,053 | 248 | [
"DDInter1526",
"DDInter1912"
] | Procarbazine | Valganciclovir | An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease. | Valganciclovir hydrochloride (Valcyte, manufactured by Roche) is an antiviral medication used to treat cytomegalovirus infections. As the L-valyl ester of ganciclovir, it is actually a prodrug for ganciclovir. After oral administration, it is rapidly converted to ganciclovir by intestinal and hepatic esterases. | Moderate | 1 | [
[
[
1053,
24,
248
]
],
[
[
1053,
63,
563
],
[
563,
1,
248
]
],
[
[
1053,
21,
29209
],
[
29209,
60,
248
]
],
[
[
1053,
25,
507
],
[
507,
... | [
[
[
"Procarbazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valganciclovir"
]
],
[
[
"Procarbazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ganciclovir"
],... | Procarbazine may cause a moderate interaction that could exacerbate diseases when taken with Ganciclovir and Ganciclovir (Compound) resembles Valganciclovir (Compound)
Procarbazine (Compound) causes Anorexia (Side Effect) and Anorexia (Side Effect) is caused by Valganciclovir (Compound)
Procarbazine may lead to a major... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.